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Abstract 
Arachnoid cyst are benign intracranial lesions with a reported prevalence up to 1.1 % 
in the population. The origin of such cysts and the mechanisms of filling and 
sustaining are poorly understood. The aim of the thesis was to characterize the 
arachnoid cyst fluid and compare it with cerebrospinal fluid from the same individuals 
to evaluate the content of arachnoid cysts, as well as to gain further knowledge of the 
mechanisms of filling and sustaining of such cysts. Patients were recruited prior to 
elective surgery for fenestration of symptomatic arachnoid cysts in the temporal fossa 
and arachnoid cyst fluid and cerebrospinal fluid was collected with written informed 
consent from 19 patients. In Paper I the content of arachnoid cyst fluid and 
cerebrospinal fluid from the same patients were compared by clinical chemistry. The 
protein content of arachnoid cyst fluid is reduced relative to cerebrospinal fluid, while 
the concentration of phosphate is elevated. The results from this evaluation indicated 
that arachnoid cyst fluid is not identical to cerebrospinal fluid. In Paper II the protein 
content in arachnoid cyst fluid from 15 patients was evaluated by qualitative 
proteomics and the findings were compared with published databases of plasma and 
cerebrospinal fluid. These comparisons indicated that the arachnoid cyst fluid 
proteome was similar to cerebrospinal fluid, but dissimilar to plasma. In Paper III we 
performed a quantitative comparison of the proteomes of arachnoid cyst fluid and 
cerebrospinal fluid for five patients. 348 proteins were quantified in individual 
patients, and 1425 proteins in a pool of the same patients using an iTRAQ-strategy 
combined with extensive fractionation. We identify differences between the fluids, but 
currently we are not able to elute the biological significance.  Searched against DNA 
and mRNA-data, we find some differences, but not in patterns of biological 
significance. This is the first quantitative proteomics comparison of AC fluid and CSF. 
In conclusion, the work presented in this thesis indicates that AC fluid is similar, but 
not identical, to CSF. Results do not support oncotic filling or valves as mechanisms 
for filling and sustaining of arachnoid cysts but rather an active or selective 
mechanism for filling.  
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Introduction 
'There are no hard distinctions between what is real and what is unreal, nor 
between what is true and what is false. A thing is not necessarily either true or 
false; it can be both true and false.' 
   - Harold Pinter, Art, Truth and Politics. Nobel Prize Lecture in 
   Literature 2005. 
In this introduction, I will focus on the previous and up-to-date knowledge of 
arachnoid cysts (AC), as well as the historical and scientific foundation of a project of 
translational science between the basal sciences of clinical chemistry and molecular 
biology, and neurosurgery. As this thesis is based on a relatively complex selection of 
methods, emphasis will be given to the theoretical basis and the technical basis behind 
the articles. I will also describe the basics of molecular biology, although familiar to 
readers trained in biology in general. I will mention but not go in to the subject of 
optimal treatment, patient selection or cut-off limits for indication of surgery. I will not 
go in to specific casuistic for clinical presentation of AC. My objective of this thesis is 
to contribute to the understanding of AC, in particular knowledge of the composition 
of the AC fluid might increase the understanding on the mechanisms for formation and 
filling. 
 
Scientific method is the tool of the trade of science. Oxford English Dictionary [1] 
defines scientific method as “method of procedure that has characterised natural 
science since the 17th century, consisting in systematic observation, measurement, and 
experiment, and the formulation, testing, and modification of hypotheses.” Scientific 
method is the continuous verification by peers that experiments show the results they 
claim, that policy and understanding of the world is based on real knowledge. The 
need for the scientific method is exemplified by the sad story of the measles-mumps-
rubella (MMR) triple vaccine scandal where Wakefield et al [2] published an article, 
later fully retracted, suggesting a relation between the MMR vaccine and autism [3].  
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The consequence of this article, even though it was fully retracted and refuted, is a 
large degree of scepticism in parts of the general population to vaccines. From a public 
health perspective, unjustified fear of vaccines causing parents to refrain from 
vaccination of their children from diseases that can be prevented is a mere tragedy. 
Scientific method is thus not only what is wrong, not only what is right, but also rather 
a tradition on how to figure that out. The scrutiny in which science is performed is not 
only from the scientist, but also from the required openness in methodology as for 
other scientists to themselves verify the results.  
 
The real purpose of the scientific method is to make sure Nature hasn't misled 
you into thinking you know something you don't actually know. 
                                Robert M. Pirsig, Zen and the Art of Motorcycle Maintenance 
 
A personal experience of the strength of academic arguments was lectures in Bioethics 
by Professor Boman at the University of Bergen in a lecture on eugenetics for the sake 
of the argument chose a supporting position, this as a challenge to young students 
unfamiliar to defending their ethics to a by far more knowledgeable debater. Science 
and university tradition is not only about the mere production of knowledge, but also 
the reflection and sense of criticism to refute a false argument. In the sense of ethical 
barriers, the scientific tradition has implemented demands of ethical regulations on the 
conduct of science, in form of the Helsinki declaration from World Medical 
Assosiation [4].  
 
For historical reasons, in particular the Nuremberg trials concerning war crimes for 
medical research purposes, the governance of ethics in medical research has been 
formalised in the period after the Second World War. This formalization of research is 
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more strict and transparent than only moral imperatives such as the Declaration of 
Geneva, based on the Hippocrates oath of moral conduct of medical professionals. 
Ethics committees have been implemented to evaluate research projects before the 
project is undertaken. Concerning publication of results, an increasing number of 
biomedical journals demand adherence to a strict set of rules set from the International 
Committee of Medical Journal Editors (ICMJE) [5], usually referred to as the 
Vancouver rules. 
 
In the general optimism of science, taking a step back to consider the theoretical 
foundation in which modern natural science is built may cause reflections on 
objective, methods and results. The popular science article “The truth wears off” in the 
magazine The New Yorker [6], is an example on such reflections, discussing decline 
in strength on a multitude of scientific experiments over time. The same argument is 
presented in formal form in the Ioannidis’ 2005 article “Why most published research 
findings are false” in PLOS Medicine [7], discussing several obvious weaknesses in 
the ordinary perspective of the scientific method. The general argument from Ioannidis 
for this is the lack of reproduction of published results, lack of independent research 
teams for verification of results, bias and specific interests in study design and 
publication, as well as lack of large-scale studies or qualified meta-analyses. 
 
Premises of science are a combination of tradition and consensus culture, not 
necessarily with further thought than what other researchers have done in the past. The 
ubiquitous boundary line of significance at 95 % set by Ronald Fischer in 1922 [8], 
was rumoured set there by no more specific reason than 5 % being a simple figure for 
pencil and paper calculations. 
 
With this in mind, I will refer the foundation for the research of this thesis. 
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1. Arachnoid cysts 
1.1 Epidemiology 
Arachnoid cysts (AC) are relatively common benign lesions of the arachnoid, with 
reported prevalence of up to 1.1 % in the general population [9-11] – a prevalence 
with large variance between studies [10, 12]. 
The aetiology and pathogenesis of AC has been controversial and still remains unclear 
[13, 14]. Primary AC is believed to be congenital malformations or developmental 
anomaly in the architecture of the arachnoid mater (AM) [14-16]. These should be 
differentiated from other types of cysts that result from CSF sequestration resulting 
from inflammation or following traumatic processes, haemorrhage or tumours; these 
can be called secondary cysts [13, 14, 16].  
 
The first report of AC is the classic work of Bright from 1831 [17], reporting a cystic 
malformation of the arachnoid layer. The 1879 report by Cunningham on the autopsy 
result of a young acromegalic patient who died from diabetes insipidus described the 
coincidence of a right hemispheric AC with a pituitary adenoma. Cunningham 
described a right hemispheric AC with a pituitary adenoma, that when opened,  “a 
large quantity of thin sero-sanguinolent fluid escaped”. This finding after a previous 
episode of strong headache suggested intracystic haemorrhage [14, 18]. The condition 
was named the “temporal lobe agenesis syndrome”, by Richard Robinson in a 
publication from 1964 [19]. Although later retracted, the term is a misnomer based on 
the wrong assumption that the temporal lobe has been underdeveloped on the affected 
side [20]. Robinson himself withdrew this. 
 
Arachnoid cysts can be located in relation to all parts of the central nervous system, 
but three out of four appear in relation to the cerebrum. Intracranial AC in adults are 
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most common in relation to the middle fossa / Sylvian fissure where two thirds are 
found, with prevalence for the left side and in males [21] [22-25]. In children, one of 
three is found in relation to the Sylvian fissure. 
1.2 Through the microscope and beyond 
AC was examined by Starkman et al in 1958 [26] observing that AC are truly intra-
arachnoid in origin, a finding confirmed by electron microscopy by Rengachary et al 
in 1978 [27]. Rengachary et al performed a histopathological study on four selected 
cases of AC [28], observing several structural features distinguishing AC membranes 
from normal arachnoid: the splitting of the arachnoid at the margin of the cyst, a thick 
layer of collagen in the wall, the absence of trabecular processes in the cyst as well as 
hyperplastic arachnoid cells in the cyst wall. The collagen is believed to be reactive, as 
a consequence of pressure while clear arachnoid cells in the wall are suggested to be 
involved in the production of collagen. A striking feature of this article is the 
observation of the inner layer of arachnoid cysts consisting of clear arachnoid cells. 
The authors observe these clear arachnoid cells to be hypertrophic and hyperplastic 
with a resemblance to observed human foetal arachnoid cells. Rengachary et al 
observed a nearly invariable association of AC with normal subarachnoid cisterns, 
suggesting AC as a congenital anomaly in the developing subarachnoid cisterns. Prior 
to the availability of CT, there was less systematic investigation of the prevalence of 
arachnoid cysts [29]. Wester [30] suggested on basis of the observed predilection for 
the middle fossa as localization of AC, a mechanism that involved a defect in the early 
folding of the brain and meningeal anlage. Sequestration of spinal fluid during foetal 
development, misfolding in development from the neural tube, the association to 
subarachnoid cisterns as well as immature arachnoid cells suggest a developmental 
defect [26, 28, 31], but the causalities remains to be unveiled. The folding pattern and 
development of structural abnormalities have been studied by several authors, but the 
timeline of appearance of arachnoid cysts is unclear [32, 33]. The observed left 
dominance of AC, especially in males, suggests a genetic mechanism of formation 
[24]. Some authors observe an association with other heritary conditions such as 
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polycystic ovarial disease (PCOS), was suggested by Schievink et al, Leung et al and 
Alehan et al [34-36] – implying a possible genetic mechanism. The observation of 
mirror image cysts in monozygotic twins also indicates a genetic mechanism of 
formation [37].  
 
 
Figure 1. Electron microscopy from arachnoid cyst membrane. (From Rengachary SS, 
Watanabe I (1981) [28], reprinted with permission) 
 18
Upper figure: Margin of the AC showing the splitting of the arachnoid membrane to 
enclose the cyst.  
Lower figure: The cyst wall is made up of dense connective tissue covered on the 
outside by thick tiers of subdural arachnoid cells. There are numerous hyperplastic 
arachnnoid cells (long arrows) especially beneath the subdural layer. There are also 
many hyperplastic arachnoid cells (short arrows) close to the cyst lumen (C). The 
dural side of the membrane is denoted by D. Semi-thin section stained with toluidine 
blue – x 510. 
 
There are three prevailing theories on the mechanisms of filling and sustaining of such 
cysts [13]; active pumps, a valve mechanism or oncotic pressure. Go et al [38] 
suggested a mechanism of fluid secretion. Based on cytochemical identification of an 
active pump in the cyst membrane, more precisely a transport ATPase in the luminal 
surface membrane, it was interpreted as evidence of secretory function. Dyck and 
Gruskin [39] suggested that osmotic pressure gradients were involved in the filling of 
the cysts, as also implied by Schachenmayr and Friede [31]. Smith and Smith[40], 
later supported by among others Santamarta D et al [41], have suggested several types 
of one-way valves as a mechanism by which fluid enters the cyst.  
 
Sandberg et al [42] performed chemical analyses of arachnoid cyst fluid and reported 
similar results as reference values for CSF, except for some unexplained with elevated 
protein content. They suggested elevated protein content as explaining factor in cyst 
filling. Helland et al [43] identified up-regulation of the Na+ K+ 2Cl- cotransporter 
NKCC1- gene in AC membrane when compared with normal arachnoid membrane. 
Several authors have by cytochemistry identified Na+ K+ adenosine triphosphatase 
(ATPase) in the membranes of AC, suggesting fluid transport [13]. Proteins co-
transporting water with electrolytes or small molecules is reviewed by Zeuthen [44], 
stating that up to 590 water molecules can be co-transported with a single molecule of 
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NaCl [45]. Thus a considerable transport of water takes place with a relatively small 
amount of electrolytes. Aarhus et al [46] analysed gene expression of the AC 
membrane relative to normal arachnoid membrane through mRNA-analyses. The 
expression profiles of 33096 gene probes were similar except for a small subset of 
nine genes, as well as some duplicated DNA regions. The authors suggested further 
analyses in larger sample sets for verification. 
 
Temporal ACs are classified according to Galassi et al [47]. Briefly, a type I cyst is 
small, biconvex, and located at the anterior temporal pole with no distortion or 
displacement of the midline of ventricle stuctures. A type II cyst involves the anterior 
and middle segments of the Sylvian fissure, extends superiorly and leaves the Sylvian 
fissure open. A type III cyst is large, involves the entire Sylvian fissure and has a 
marked radiological mass effect with displacement of not only the temporal lobe, but 
also the frontal and parietal lobe. 
1.3 Clinical presentation 
Most symptoms caused by an AC are non-specific and without sudden deterioration, in 
contrast to acute haemorrhages or stroke. Neither are the symptomatology necessarily 
progressing, such as might be the case for intracranial tumours.  
 
In children, AC cause signs of increased intracranial pressure, such as headache, 
vomiting, lethargy, papilloedema, abnormally increasing head circumference, and 
seizures [16, 20, 25, 48, 49]. Signs of elevated intracranial pressure occur in more than 
50 % of cases and are the leading symptom on admission. The other symptoms are 
mostly related to the cyst location; seizure disorders are reported in 18.2 % of patients 
and focal signs corresponding to the cyst are found in 31.9 % [16]. 
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The most common complaint in adults is headache, followed by seizures, dizziness, 
dyscognition and focal neurological deficits. [14, 20, 25, 50-53]. In adults, clinical 
improvement after surgical decompression is not related to cyst size [20]. 
   
AC may grow over time, which may increase clinical symptoms due to increased 
intracranial pressure [54, 55], but most cyst don’t seem to grow [56].  
1.4 Surgical treatment 
Treatment options for AC have included cyst aspiration, cyst excision, cystoperitoneal 
shunting, cyst fenestration, cystocisternostomy, marsupialisation in the subarachnoid 
space and ventriculocystostomy [53]. Currently, the treatment options of AC are 
fenestration or ventriculoperitoneal shunting. In fenestration, the cyst is operated either 
by craniotomy or by endoscopy [22, 57] creating an opening to the subarachnoid space 
surrounding the cyst. A ventriculoperitoneal shunt is a system draining the content of 
the cyst to the peritoneum with the objective of reducing the size of the cyst. 
Most authors prefer fenestration as treatment of choice, either endoscopically or by 
open surgery, rather than shunt-related complications [23, 58, 59].  Although still 
debated, cystoperitoneal shunting is readily performed due to low invasiveness and 
safety [58, 60]. 
There is a significant controversy concerning when, if at all, surgical treatment for 
arachnoid cysts is indicated [25][52][53].There is also a controversy on which 
procedure is the optimal treatment [61]. In principle, the controversy of surgical 
indication is a question on when the symptoms are sufficient for the patient to be 
operated, as well as to which degree more diffuse symptomatology can be used as 
indication for surgery but it is also a discussion of whether or not the benefits from 
treatment overcome the risk of the procedure. 
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2. Proteomics, laboratory methodology, medical 
research and molecular biology 
2.1 Cerebrospinal fluid 
The cerebrospinal fluid (CSF) is the clear liquid surrounding the brain, protecting the 
brain from shock and preventing strain from the weight of the brain. The CSF is 
bordered between the arachnoid mater and the pia mater, the middle and the inner of 
the three meninges covering the brain, filling ventricles of the brain, around the spinal 
cord and in the central canal. The CSF is primarily produced in the choroid plexus in 
the lateral ventricles. The production of CSF is about 500 ml /day, while the CSF 
space is at about 130-150 ml. The resorption of CSF is primarily in the arachnoid 
granulations; bulky ports to the sinus sagittalis superior, a part of the cerebral vein 
system.  
 
The protein concentration in CSF typically ranges from 0.2 to 0.8 mg/mL, which is 0.3 
– 1 % of the plasma concentration [62, 63]. Around 20 % of the proteins in CSF are 
CNS derived, and the remaining 80 % derives from blood [63, 64]. The CSF both 
gains and loses content during its circulation through the CSF space in and around the 
CNS, representing challenges and opportunities for research. It is a general consensus 
that markers of disease in an organ will be found in higher concentrations in body 
fluids in close proximity to the organ in question [65] than elsewhere. The CSF with 
its close passage to the brain tissue is suggested as a body fluid suitable for 
investigating cerebral pathology [66]. The blood-brain barrier (BBB) is relatively 
impermeable to a multitude of substances, causing the passage of liquids, salts, 
proteins and other substances to the CSF to be selective. The brain-CSF barrier 
(BCSFB) is a much more permeable membrane than the BBB, allowing a higher pace 
of diffusion of substances between brain parenchyma and CSF. The mechanisms of 
passage in these barriers are not fully understood. The total protein content and 
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composition is dependent on several variables. Location of sample collection is thus 
not necessarily indifferent [62]. 
2.2 Ethics 
Laws and science consensus regulate the involvement of human specimens in 
research. In Norway, studies like the present require informed consent. The project, 
with description of objective, as well as how the study is performed and procedures for 
written informed consent is supervised and approved by a Regional Ethics committee 
(REK). The Data Protection Authority approves the creation of biobanks of patient 
sample material. Publication of results is regulated by the International Committee of 
Medical Journal Editors (ICMJE) Uniform Requirements for Manuscripts Submitted 
to Biomedical Journals [5]. The current study is in accordance with the regulations on 
ethics and biobanking as well as the uniform requirements by ICMJE.  
2.3 Sample handling 
A current challenge in providing good analytic data is the collection of representative 
sample material. This should be handled in such a way that no variation is introduced 
to the sample material before analysis. The analysis setup should be planned using the 
same instrument with the same instrumental settings and interpret the result in the 
same manner for all samples or patients included.  
Before a set of sample is analyzed, the collection, aliquotation and sample handling 
happens at different times, and the time of storage is different. It is important to 
standardise the collection methods as well as storing of samples in such a manner that 
degradation is reduced to a minimum. An example of good sampling procedure is the 
consensus protocol of the European Network for Biomarkers in MS, BioMS-eu, by 
Teunissen et al [67]. The work by Berven et al [68] concerning degradation in the low 
molecular weight proteome with different storage conditions demonstrate the need for 
adhering to standardised collection methods. The work by Kraut et al [69] illustrates 
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the importance of standardised selection of storage tubes, especially on hydrophobic 
peptides over time.  
Standardization of sample handling should cover every step from the method of 
sample collection, centrifugation speed, time limits before ultra freezer or dry ice, the 
use of refrigeration before centrifugation and the choice of storage tubes and 
equipment [70]. 
2.4 Clinical chemistry 
The term ”clinical chemistry” refers in medicine to analyses of the major electrolytes, 
minerals, cells and some abundant relevant proteins and enzymes in body fluids. In 
patient diagnostics analyses are performed in a standardised manner, mostly by 
hospital laboratories. Clinical chemistry is readily available in bedside diagnostics and 
plays an important part in clinical decision-making. For both clinical and research 
purposes, clinical chemistry makes up a significant complement to a multitude of 
problems. It is a readily available way to explore biology as well as it for most clinical 
chemical analyses, represents a limited invasive sampling of patient material.  
2.5 Molecular Biology  
Warren Weaver coined the name Molecular Biology in 1938 on basis of the ideal of 
physical and chemical explanations of life. Molecular Biology is a branch of biology 
that deals with the molecular basis of biological activity and consists of studies of 
form and function of the molecular machinery and blueprint of life itself. In practice, 
molecular biology studies the various forms of cells and cell compartments, as well as 
the study of DNA, RNA and proteins [71].  
 
The central dogma of Molecular Biology was first stated publically in a rather brilliant 
article by Francis Crick in 1958 [72] and briefly revised in a Nature paper in 1970 
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[73]. This central dogma describes the information transfer between DNA, RNA and 
proteins, more specifically that information once it has reached the protein, cannot be 
transferred back to either nucleic acids.  
 
 
Figure 2. Central dogma of Molecular Biology (Illustration adapted from Crick, 
Nature 1970 [73]) 
2.5.1 DNA 
DNA - deoxyribonucleic acid is based on a relatively simple chemical backbone of 
phosphate and the sugar deoxyribose with attached one of four nucleobases adenine, 
thymine, cytocine and guanine – with specific pairing of adenine to thymine, cytocine 
to guanine creating the double helix. DNA is the building material, the code in which 
our genetic material is written. The segments of DNA that contain specific information 
are called genes. Although not all DNA is genes, large segments of DNA have a 
regulatory function on the expression of the actual genes. The DNA is organised as 
rings in relatively simple organisms such as bacteria, while it in more complex 
organisms is folded up and organised by histons, separated on different chromosomes 
[71]. Although the code of DNA consists of only four possible inputs, the nucleobases, 
the possible information output is immense. 
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In the history of genetics, some experiments have made a leap in the understanding of 
the way information transfer is performed. Avery–MacLeod–McCarty [74] 
demonstrated in 1944 that genes are made up from DNA and that DNA is the heredity 
material of bacteria. Watson and Crick [75] presented the organisation of DNA in the 
double helix DNA model. The understanding of the copying machinery of DNA was 
demonstrated in the Meselson-Stahl experiment, showing copying of DNA as a semi-
conservative process [76]. The understanding of structure did not make the 
information available for analysis straight away. This did not happen before Sanger 
and co-workers developed the method using modified nucleic acids 
(dideoksynuclotide tri-phosphates (ddNTPs)) to terminate chains in duplication for 
sequencing [77].  
 
Before this, several scientists did experiments on inheritance and specific traits. 
Charles Darwin published his On the Origin of Species in 1859 [78], exploring natural 
selection and adaptation to environment. Gregor Mendel presented his results from 
garden crossbreeding in 1865 [79], although Mendel’s rules were not recognised until 
after the pattern of inheritance was rediscovered in 1900.  
 
Optimism of understanding the human genome was at its greatest at the time of the 
first publications about the sequence of the complete human genome. Two separate 
projects, one from The International Human Genome Mapping Consortium and one 
private from Celera Genomics and Craig Venter were published just a day apart, 
February 15th 2001 in Nature[80] and February 16th 2001 in Science [81], respectively. 
Since then, the understanding of further complexity has increased with the recognition 
of the role of epigenetics. 
 
Epigenetics refers to inheritable information encoded by modification of the genome 
and chromatin components that affect gene expression. Thus, epigenetic changes do 
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not modify the DNA sequence. Epigenetic modification does not follow Mendelian 
inheritance and may be reversible. Epigenetics in DNA refer to key areas such as 
histone and chromatin remodelling and methylation of DNA. As a phenomenon, 
epigenetics is not restricted in DNA, but might also be seen in RNA and proteins – the 
complexity is only beginning to be unveiled. As Taft et al state in their 2010 review 
[82]: 
 
“The absolute number of protein-coding genes encoded by a genome is 
essentially static across all animals from simple nematodes to humans, 
indicating that additional genetic elements must be involved in the development 
of the increasingly complex cellular, physiological and neurological systems”  
 
2.5.2 RNA 
The understanding of RNA as a separate entity evolved in parallel with the research on 
DNA. RNA differs from DNA in some simple features. The RNA is single-stranded 
and may be folded and bent in to complex structures, an effect which is partially 
caused by the lack of rigidity in the structure created from its backbone sugar, ribose. 
The protein translation mechanism from RNA in three separate entities; transfer RNA, 
messenger RNA and ribosomal RNA, is complex. The understanding of how the 
mechanism works was delayed several decades until the recent advent of structural 
biology. As Alexander Rich states in his 2009 review paper [83]  
 
“The hybrid DNA–RNA helix remains the bedrock of information transfer in 
biological systems. The existence of a hybrid helix seems so obvious today that 
young researchers simply take it for granted. There is little realization of the 
extent to which scientists once wrestled with the question of how helical 
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polynucleotides with different conformations could react together to make a 
stable hybrid duplex structure”  
 
 
Figure 3. Schematic overview of the structure of DNA and RNA with its backbone of 
nucleobases.    (from Wikimedia.org, free commons licence) 
 
Transcription and regulation of ribosomal RNA, messenger RNA, and transfer-RNA 
from DNA is not direct and one-to-one, but rather modified caused by introns and 
exons from the first transcript of RNA. The ribosomal RNA forms the ribosome, 
which is the protein transcription machinery. The messenger RNA works as a template 
for proteins, while the transfer RNA collects amino acids as building blocks in to the 
ribosome and “bridges” to achieve a correct and precise translation of RNA to protein. 
Less than 2 % of the total RNA transcripts from DNA is transcripted into coding 
mRNA. Previously the remaining 98 % of DNA was given the misnomer term “junk-
DNA”. Several authors point out a consensus in the scientific community, that there is 
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no logic to maintain such an energy demanding process without a function. Now, the 
function of “non-coding DNAs” is just beginning to be discovered [71, 82, 84]. Until 
2010, 30 people have been rewarded Nobel Prizes for research on RNA, the latest in 
2009, where Ada Yonath, Venkatraman Ramakrishnan, and Thomas Steitz were 
awarded the Nobel Prize in Chemistry for their structural work on the ribosome and 
translation mechanisms [85, 86]. 
 
Figure 4. From DNA to protein, transcription from DNA and translation from mRNA 
to protein. Proteins are built from amino acids represented as dots, by tRNA. 
     
(from Wikimedia.org, free commons licence) 
2.5.3 Proteins 
Proteins are long chain molecules consisting of one or more polypeptides composed of 
20 different amino acids as building blocks, encoded by the mRNA. The peptide is a 
single polymer of amino acids linked with amide bonds, where the –NH-C(R)-(C=0)- 
amino acid common part is a small and repeating flexible backbone which provides a 
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flexible and foldable structure. The residues of the amino acid backbone create a 
potential for folding and union of several peptides into proteins. The folding is either 
spontaneous or assisted by the cellular machinery. The folding of proteins happens in 
such a manner that specific sequences of amino acids fold dependent on amino acid 
sequence. These regions again fold up such as polar groups fold towards each other or 
towards polar solutes, apolar groups towards each other or end up in lipid membranes, 
folding is dependent on amino acid polarity. The structure is also stabilised by thiole (-
SH) groups create a potential for sulfur bridges (-S-S-) fixing superstructures of 
proteins. These processes create a multitude of protein structures, from the simple 
cellular structures such as alfa-helixes or beta-sheets to more complex metal ion 
binding proteins such as zink fingers. 
 
The functions of proteins are thus not solely explained by the sequence of amino acids, 
but rather depends on a three dimensional structure built through folding and linkage 
of several peptides. The structure of a protein is differentiated in levels, where the 
primary structure is the amino acid sequence, the secondary structure is mainly the 
composition of alfa-helixes, beta-sheets and loops, and the tertiary structure is the 
spatial folding of these structures fitting together with polar attraction as van-der-Waal 
forces, hydrogen bonds and disulfide bridges. The quarternary structure of a protein is 
the union of several peptides forming the protein, sometimes also with cofactors [71].  
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Figure 5. Quarternary structure of haemoglobin, of four haemoglobin (2 alpha, 2 beta) 
chains each with heme cofactors.  
(Adapted from Wikimedia.org under creative commons licence) 
 
Proteins with its small and flexible backbone as well as a much larger variation of 
substituent groups than RNA and DNA, as well as the huge versatility in structure and 
folding, is the reason how proteins perform most of the cellular functions. Proteins 
construct receptors and signal substances, ion channels and mechanisms for 
metabolism and energy generation, cellular transport, machinery for cell division, 
movement and linking. The flexibility in structure and function is thus much larger in 
proteins than in RNA. While life itself may have started as RNA, it has most certainly 
evolved through proteins.   
 
2.6 Proteomics 
Wasinger and Wilkins introduced the term proteome in 1995, referring to “the 
PROTEin complement expressed by a genOME” [63, 87, 88]. As a field of research, 
this includes tracking of single proteins’ structure and function, of groups of proteins 
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present or not present in a sample material, appearance of proteins specific for a 
condition as a biomarker of a biologic process or measuring specific changes in 
concentration of proteins as markers of biologic changes. An organism’s proteome is 
determined in part by the genome encoding the primary amino acid sequence. Other 
factors affecting a proteome include alternative splicing variants, post-transitional 
modification (such as phosphorylation and ubiquitylation) and protein cleavage. Taken 
all possible variations into account, the potential number of protein species in a cell is 
far greater than the number of genes. Adding to the complexity, the proteome of a cell 
is not static, but may change in response to both internal cellular state and the external 
environment [89]. Proteins, or polypeptides in general have traditionally been 
sequenced by cutting off one amino acid at a time from the peptide chain, and 
thereafter identified each amino acid identified by UV spectroscopy, a method termed 
Edman degradation [90]. This field of research is in rapid development both in science 
and with respect to innovative instrumentation and methods that enable the research to 
be performed.  The development of advanced mass spectrometers coupled with high-
pressure chromatography over the last ten years has enabled a leap in detection limits 
and possibilities for specific detection of proteins present in low concentrations in a 
mixed matrix. 
2.7 Gel electrophoresis 
Until a few years ago, most separation science as well as staining and identification 
has been performed by gel-electrophoresis, both one and two-dimensional 
experimental setup. The principle of gel-electrophoresis is utilizing a gel based on 
agarose or polyacrylamide to separate denatured proteins; during electrophoresis the 
drift is roughly proportional to the protein mass. 2D electrophoresis applies a 
separation on isoelectric focusing before ordinary electytophoresis. This creates a pI 
gradient along the x-axis, and a MW gradient along the y-axis. Although a separation 
is performed, this method has limitations both on the minimal amount of proteins that 
has to be loaded for analysis, as well as the ability to identify, select and extract 
proteins from the gel. There are several advanced procedures for staining and 
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identification on gel electrophoresis, such as coomassie brilliant blue [91], Sypro ruby 
[92] and Silver staining [93] each with its advantages and drawbacks [94]. The 
proteins present have to be compared between different gel sheets for different 
samples, creating a challenge concerning reproducibility to the matching between 
samples, as well as challenges to missing values in samples [95] There is also a 
limitation on the dynamic range of the analysis, defined as the difference in 
concentration between the weakest and strongest “spot” on the gel.  
2.8 Trypsin / tryptic digest 
Trypsin is a protease, a pancreas enzyme that cleaves peptide chains mainly at the 
carboxyl site of the amino acids lysine and arginine, except when either is followed by 
the amino acid proline [96]. The principle of cleaving proteins to peptides is to make 
the sample available for mass spectrometry - a necessity for mass spectrometry as the 
polypeptides is analyzed as ions.  Another advantage of cleaving proteins to 
polypeptides is the relatively equal size between different protein fragments, allowing 
reproducible and reliable chromatography. Tryptic cleavage is an essential part of the 
proteomics workflow and the enzyme has become a workhorse in proteomics.  
 
Figure 6. Hydrolysis of proteins by trypsin (figure from clcbio.com under creative 
commons licence).  
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2.9 Chromatography 
Chromatography is a term describing separation science of molecules, and is 
performed with a multitude of materials, solvents and analytes. For proteomic 
purposes, liquid chromatography has taken over for the separation function previously 
performed by gel electrophoresis [94, 97-99]. Reverse phase (RP) miniaturised high-
pressure liquid chromatography (HP-LC) is the predominant separation technique in 
proteomics, both offline and coupled to mass spectrometers. These are columns with 
an apolar column material, typical C-18 on a silica backbone. Its miniaturization, 
implying reduced volumes and reduced inner diameters for the columns, causes a more 
precise separation without wasting sample material in the separation columns, 
supported by high-pressure pumps to overcome the resistance in the system. The 
principle for reverse phase chromatography is to use a non-polar stationary phase at 
the inner covering material of the chromatography columns and elute a gradient from 
polar to non-polar solvents consisting of water and water miscible organic solvents 
such as acetonitrile (ACN), acidified by formic or tetrafluoroformic acid (TFA). In 
such a column, the very polar substances, such as salt and impurities, will often leave 
first, following a gradient of peptides based on size and polarity. 
The ion exchange chromatography (IEX), in particular strong cation exchange (SCX) 
chromatography and strong anion exchange (SAX) chromatography are useful 
techniques, as they are mostly orthogonal to reverse phase chromatography. The 
principle in cation exchange is that the stationary phase is negatively charged so 
positively charged molecules (peptides) interact by ionic interaction to the solid 
support. A mobile phase, with a pI/pKa between the charged molecule and the solid 
support will elute the peptides based on a change in pI gradient on basis of acid 
buffered salts.  Equivalent for strong anion exchange, a positively charged column 
bind negatively charged peptides, which are eluted on basis of pI gradient. 
Disadvantages of such orthogonal chromatography are the need for removal of large 
amounts of salt-containing solvent. A relatively new solution to this problem has been 
combination columns, termed mix-phase columns such as reverse phase-weak anion 
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exchange (RP-WAX) combined columns [100]. This is a system set-up with a mobile 
phase changing on both polarity and pH, such that peptides are separated better than 
either of the single modalities, without the need to desalt the sample before analysis. 
The principal advantage here is separation with less introduced complexity. 
2.10 Mass spectrometry 
During the last ten years, proteomics has switched the analytical platform from gel-
based to mass spectrometry-based techniques [63, 89, 99]. In the years just after 2000, 
optimism was great to “high-throughput methods” such as MALDI-TOF, short for 
matrix assisted laser desorption/ionisation – time of flight mass spectrometry, and 
SELDI, which is a version of the same with specific surfaces to improve ionization. 
MALDI is a method to make ions enter a mass spectrometer, introduced by Karas et al 
[101, 102]. Briefly, the sample is placed on a surface and mixed with a matrix for 
ionization, often consisting of small organic acids such as sinapinic acid or other 
substituent molecules from cinnamic acid. While the precise mechanism is not fully 
understood [103], the principle is that the dried sample-matrix spot is ionised with a 
laser, resulting in vaporised charged particles able to enter the mass spectrometer. 
MALDI is a stable, quick and simple method for analyzing samples. As a method, it 
does not permit chromatography in itself; this must be performed off-line before 
spotting. In general the mass resolution, meaning the instrument specific ability to 
separate two specific similar masses, of a MALDI-TOF is not high enough for high 
confidence peptide identification [103].   
Several research groups developed over many years MALDI as a principle and method 
for ionization. Koichi Tanaka was awarded a part of the 2002 Nobel Prize in chemistry 
for demonstrating that a combination of laser wave length and energy to a matrix with 
corresponding physical and chemical properties could cause a soft ionization [104], a 
prize John Fenn also took a part in for the development of electrospray ionization 
(ESI).  
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Electrospray ionization mass spectrometry (ESI-MS), introduced by Fenn et al in 1989 
[105], has enabled analyzes of samples in a mass spectrometer without being 
dependent on matrixes or specific surfaces for ionization. The principle is as for 
MALDI to perform a soft ionization of peptides, where soft meaning ionization 
without breaking structural chemical bonds – as opposed to hard ionization with 
fragmented ions. ESI-MS is in use for many different types of mass spectrometers, 
both offline and coupled to high-pressure liquid chromatography (HPLC). The 
advantages for coupling to liquid chromatography (LC), especially at low flow in 
small bore columns for HPLC, is the increase in sensitivity when allowing instruments 
to analyze fractions of one sample separated over time, still allowing for the use of 
small sample volumes. A typical simple HPLC setup for a proteomics mass 
spectrometer is a reverse phase non-polar column of silica –C18, with a mobile phase 
being polar to nonpolar gradients of water and acetonitrile (ACN), added a minute 
amount of formic acid. The chromatography column ends directly to the ESI, and the 
chromatographed sample is continuously injected in the mass spectrometer. The 
typical gradient time is some 60-80 minutes, gaining a separation over time for the 
content of the sample – thus allowing the MS instrument to thoroughly analyze, 
fragment and identify peptides as they appear eluted from the chromatography 
column.  
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Figure 7. Mass spectrometry principle 
 
There are several different forms of mass spectrometers, with different qualities [99, 
106, 107]. In principle, the mass spectrometer consists of three parts, the ion source, 
the mass analyzer and the detector (see figure X).  
 
ESI and MALDI are ion sources, converting a peptide from a solid or solubilised form 
to a gaseous charged molecule capable of “flying” in electric fields in vacuum. There 
are several other modalities than ESI and MALDI in ion sources, but for most mass 
spectrometers in proteomics, ESI is by far the most predominant. 
 
Mass analyzers separate ions depending on mass per charge (m/z) in an electric field 
and can perform different functions, depending on architecture. The range is from 
simple separators of ions based on mass per charge to the more complex combined 
units where a mass spectrometer is coupled to collision cells selecting and fragmenting 
separated ions (MS-MS). This fragmentation divides the peptide in smaller random 
fragments, mainly with the purpose on basis in statistics to reconstitute the sequence of 
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amino acids in the peptide, as well as to free of reporters for labelled tags for analysis, 
further discussed under “quantitative proteomics”.  
 
The detector is recording individual m/z from the separated peptides, and also the 
number ions hitting the detector, thus providing grounds for determining relative 
intensity of ions present.  
 
 
Figure 8. Peptide fragmentation patterns. The figure represents fragmentation patterns 
in principle in an amino acid chain, where b/y – ions, separation in the (C=O)-N-H 
amide bond is the most common (figure from Wikimedia.com under creative 
commons licence, adapted from Roepstorff [108]). 
 
The principle of quadropole mass spectrometers [107] is that a filter passes ions 
through chambers limited of charged rods, where ions can be selected to pass through 
on basis of ion resonance of m/z. Only specific m/z molecules are able to pass, and can 
therefore be separately measured by a detector behind the quadropole. A quadropole 
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cell in this instrumental set-up can also be used as a trap, confining selected ions to a 
limited space before being passed further within the instrument.  
Single quadropoles itself are not very specific, but they are often combined with other 
modalities or placed in sequence. Linear trap quadropole mass analyzers (LTQ) 
consist in principle of three quadropoles in a row. LTQ instruments are able to select 
for specific masses in the first quadropole, colliding and fragmenting in a second 
quadropole and again analyzing the fragments of masses selected in a third. This gives 
information of the content of specific peaks identified in the mass spectrum, giving 
opportunities to follow specific fragments of peptides – a very useful feature for 
selected reaction monitoring (SRM) [109, 110], further discussed in the section 
“quantitative proteomics”. SRM is a label free technique to follow specific fragments; 
it is not necessary to “scan” the whole mass spectrum. This gives an increase in 
instrument sensitivity of one to two orders of magnitude [109].  
 
 
 
Figure 9. Triple quadropole experiment linked to LC-ESI in a SRM setup. The first 
quadropole selects peptides as a filter for further analyses, the second quadropole 
fragments the selected peptides, and the third select fragments for analysis.  Figure 
adapted from Lange [109] under Creative Commons licence. 
 
Time of Flight (TOF) mass spectrometry is a more specific mass analyzer than 
quadropoles. Ions enter and the m/z is measured on basis of their flight time through a 
charged vaakum tube. This is a versatile and stable mass analyzer and is the common 
mass analyzer for MALDI.  
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Detectors of TOF and trap-instruments are of electron multiplier types, and they 
typically add up information with a trap to detect the m/z and relative intensity of a 
molecule. Such detectors work by principle of an emissive material, such as if a 
charged particle hits the detector, several electrons might be emitted and each lead to 
new emissions, causing the generation of a detectable current on the end plate [111]. 
 
A Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FT-ICR-MS) 
applies another principle of detecting masses. Ions are gathered into an ionization 
chamber and are exited in a magnetic field cyclotron.  Detectors measure the 
movement or orbit of ions in the cyclotron. The signal decay from excitations of ions, 
known as free inductance decay (FID), is detected and transformed to resonance 
frequencies by Fourier transform and these frequencies are proportional to 
mass/charge. These mass analyzers have high resolution and can be used for a precise 
measurement of masses. Orbitrap MS applies the same principle as FT-ICR-MS, using 
an oscillating electric field instead of an expensive superconducting magnet [90]. The 
principle is to inject ions to the Orbitrap observing the stabilizing of an orbit based on 
electrostatic attraction and centripetal acceleration, depending on m/z. The m/z of 
trapped ions is thus easily deductible by Fourier transform detected ion orbits, where 
resolution is increased on every ion “passing” the detector in its orbit. Orbitrap MS 
instruments are well described by Hu et al [112] and Olsen et al [113]. 
 
2.10.1 Challenges for mass spectrometry in proteomics 
The difference in concentration between the most abundant proteins and proteins of 
possible interest that exist in lower concentration is a large challenge in proteomics. 
For any instrumental set-up, the difference between the most abundant protein in 
concentration and the one with lowest concentration detectable is termed the dynamic 
range. The dynamic range is often measured in orders of magnitude, where most 
instrument set-ups can handle 104-106, while the biological systems subject for 
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methodology relevant for this thesis, cerebrospinal fluid and plasma is up to 1010-1011. 
This can be exemplified further. Using plasma as an example, the concentration of one 
single protein – albumin, makes up for about 2/3 of the total protein content of about 
60 g/litre. Added up, immunoglobulins, blood coagulation factors fibrinogen and 
lipoproteins together with albumin make up for 99 % of the protein content in plasma. 
Therefore, a strategy is needed to overcome that problem.  
 
Spreading the proteins entering the mass spectrometer over time by chromatography is 
a strategy much employed to allow the instrument to focus at a few polypeptides at a 
time. Still, the abundant proteins tend to dominate any sample due to their sheer 
numbers. Several approaches have been applied in proteomics; unspecific depletion of 
abundant proteins, specific immunoassay targeting of selected proteins to selectively 
remove abundant proteins, and extensive fractionation prior, to analysis.  
 
Removal of high abundant proteins from body fluids can be conducted in several 
different ways, but the most recognised approach is to use columns with antibodies 
agains the most abundant proteins. Examples of such columns are MARS (multiple 
removal affinity system) from Agilent, Seppro IgY from Genway Biotech, and 
Proteoprep from Sigma. Each vendor has several different and more complex columns 
absorbing more high-abundant proteins from a sample. For the future, this might be 
expected to further increase the feasibility of analysis of low-abundant proteins.  
2.10.2 Alternatives to mass spectrometry in proteomics 
Antibodies can also target directly the specific protein in question, by methods such as 
Enzyme-linked immunosorbent assay (ELISA) and western blot. The principle of 
ELISA is to create an assay where the substance in question is attached to a surface or 
solid support by antibodies; a new “detection” antibody is then attached with a 
reporter, such as an enzyme so that, by measuring enzyme activity, the amount of a 
protein is reported by indirect measures. This is a useful method for control procedures 
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and routines, but not in the discovery phases. Western blot is more useful in 
proteomics, especially in hypothesis-driven proteomics. A western blot consist of a 
separation on a gel, transfer to a membrane, incubation with primary antibody against 
the protein in question, and later incubation with secondary antibody against the first, 
attached to a reporter enzyme. Gel electrophoresis, as previously mentioned, has been 
the traditional alternative to mass spectrometers, but is on a decline due to sensitivity 
and reproducibility issues. 
2.11 Quantitative proteomics 
Quantitative proteomics is defined as methods able to quantify absolute or relative 
differences in protein concentrations between a sample and a control or reference. 
Kroksveen et al wrote a concise review article concerning quantitative proteomics and 
neurological diseases [70]. They discuss several methods for quantitative proteomics, 
chemical isotope labelling, label free and MS/MS- based methods. 
 
In label-free quantitative proteomics, proteins are quantified either by spectral 
counting or by intensity measures. In spectral counting, the number of spectra 
containing fragments selected for identification represents the relative quantity of a 
protein [70, 114]. Label-free quantitative proteomics by peak intensity utilise the 
configuration of the peak between two samples as a measure of quantity, either 
measuring the highest intensity or the integral of one or more peaks to represent the 
relative intensity between two samples [70, 115, 116].  
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Figure 10. Strategies for peptide quantitation. 
A: Stable isotope labelling, with a heavy and a light tag. 
B: Isobaric tandem mass tag, where the tag separate in MS/MS and the same peptides 
are separated by 1Da. Quantification is by relative quantities to a standard, one of the 
tags. 
C:  Selective (SRM) or multiple reactions monitoring (MRM) where quantification is 
based on relative abundance to internal or external standard.  
Adapted from Domon [90], reprinted with permission from AAAS 
 
A method for performing quantitative proteomics is iTRAQ – isobaric tag for relative 
and absolute quantitation, first published by Ross et al in 2004 [117]. This is a 
commercial kit from Applied Biosystems (Life Technologies, Carlsbad CA, USA). 
This is one of several methods utilizing reporter ions attached to peptides from 
different samples or sample fractions, which is then mixed and analyzed together by 
MS/MS and the relative quantities of proteins in mixture appear in the spectra. The 
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method works by attaching reporter ions separated only by 1 Da MW to free amines in 
the peptides. The term “isobaric” means that the reporter before fragmentation is 
attached to a weighted molecule, so that the different labelled groups will have equal 
mass. The reporter ion will follow through MS fragmentation and disintegrate and 
separate in MS/MS-fragmentation, giving peak heights representative of relative 
quantity of each protein The typical workflow of such a procedure is to have a known 
and equal amount of protein in each sample, deplete the more abundant proteins, 
digest the proteins to peptides with trypsin, add the different reporter ions to the 
different samples and mix, fractionate the sample by off-line HPLC, and analyze each 
fraction by LC-MS/MS. The reporter released after MS/MS, termed by mass 114, 115, 
116 and 117 will be detected as four separate peaks, where signal intensity is a relative 
measure of concentration of the same peptide between samples. 
 
 
 
Figure 11: Structure of reporter ions attached to peptides. Adapted from Ross et al 
[117] 
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Figure 12. Mass spectrum of iTRAQ reporter fragmentation pattern. Adapted from 
Tweedie-Cullen et al [118].  
 
2.12 Clinical plausibility 
The objective of proteomic studies is in general to identify specific changes at a 
molecular level representing the disease or phenomenon in question. Given that a 
change, either by the presence or changed concentration of a specific analyte, is 
present in a large number of “diseased” samples but absent in controls, then it might 
be used to discriminate an unknown sample (or patient) to have or have not the 
specific condition in question. An analyte or a set of analytes in combination is termed 
a biomarker. The principle specified for proteomics will be as proteins perform a 
multitude of cellular functions, a change in function will be found in a molecular scale 
and thus a change in protein content will mirror a change in function. 
For proteomics, there are yet not any large-scale biomarkers which have been 
approved for clinical use, as is emphasised by Ioannidis [119] who identified four 
major causes for this failure. Clinical reversal, exemplified by the prostate specific 
antigen, does not show as promising results in clinical practise as was expected upon 
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its introduction. Validation failure is when initial promising analytes fail to provide 
analytical validity in an external sample set. Non-optimised clinical translation is when 
the analytes selected for further development is not the most promising but the more 
available for a research group, as well as a smaller sample size gives a skewed 
presentation of reality. Promotion despite nonpromising evidence is when biomarkers 
are taken further from discovery phase even though results from research should 
indicate further discovery research – either for commercial or non-science causes.  A 
roadmap for implementation of clinical proteomic biomarkers is well evaluated by 
Mischak et al [120]. 
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3. The Thesis 
3.1 Aim of the Thesis 
The main objectives of the thesis were to characterise AC fluid by clinical chemistry 
and proteomics and compare it with CSF from the same individuals. This information 
would be used to gain knowledge of where AC fluid comes from, as well as the 
mechanisms of filling and sustaining of such cysts.  
 
Secondary objectives were 
1. Compare the clinical chemistry between AC fluid and CSF 
2. Evaluate the proteome of AC by qualitative proteomics by comparison to 
published databases of CSF and plasma proteomes 
3. Compare AC fluid and CSF proteomes by quantitative proteomics 
4. Evaluate the results of analyses versus previous studies on mRNA and DNA of 
AC 
3.2 Materials and Methods 
Patients were recruited by the responsible surgeon prior to elective surgery for 
fenestration of symptomatic AC in the temporal fossa. AC fluid and CSF was 
collected with written informed consent from 19 patients, age 22-78, nine females and 
ten males in the period January 2008 to September 2010.   
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Patient Age (yrs), sex Side Galassi-stage[47] Remarks 
1 26, f Left 2  
2 43, m Left 2  
3 58, f Left 3 Old hematoma 
4 34, f Left 2 Reoperation 
5 22, f Right 1  
6 36, f Right 2 Slight hemolysis CSF 
7 35, f Right 2  
8 77, f Left 1  
9 42, f Left 1  
10 60, m Left 2 Slight hemolysis CSF 
11 56, m Right 2  
12 25, m Left 1  
13 30, f Left 1  
14 37, m Left 2  
15 63, m Left 2  
16 58, m Right  
(Bilateral) 
1 Bilateral, opposite already operated 
17 62, m Right 1-2 Chronic SDH. Thin membrane 
between AC and SDH. Slight blood 
contamination. 
18 63 m  Right 3 Reoperated. Shunt. Previous 
meningitis x2, multiple previous 
intracranial operations. 
19 50, m  Left 1  
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Table 1: Patients included in the study.  
3.3 Ethics 
This project was approved by The Regional Committee for Medical and Health 
Research Ethics (REK) of Western Norway (approvals REK 70.03, NSD 9634 and 
REK 2009/1885).  
3.4 Surgical method and sample collection 
All patients were operated with a craniotomy under general anaesthesia, given as total 
intravenous anaesthesia (TIVA) with propofol and remifentanyl. Vecuronium bromide 
(Norcuron®) was used as the neuromuscular blocking agent. A burr hole was made 
with a high-speed drill immediately posterior to the sphenoid wing in order to gain 
access to the anterior and most basal aspects of the middle cranial fossa. The dura and 
the underlying cyst membrane were punctured through the burr-hole with a 23 G, 25 
mm long syringe connected to an Optidynamic® spinal fluid manometer (Mediplast 
AB, Malmo, Sweden). After pressure equilibration and registration, a cyst fluid sample 
(3 - 5 ml) was collected using the manometer tube as a siphon. The sample was 
immediately transferred to a sterile centrifuge tube for centrifuging and further 
analytic processing as described below (sample handling). After this procedure, a 
standard craniotomy with a microsurgical resection and fenestration of the cyst 
membranes was performed. Before opening the medial cyst wall and thus 
communicating the cyst interior to the basal arachnoid space/CSF, all cyst fluid was 
aspirated from the cyst cavity to avoid cyst fluid contamination of the CSF.  
After opening the medial cyst membrane that covered the basal structures (the tentorial 
slit, the oculomotor nerve, the carotid artery, and the optic nerve), thus creating 
communication to the basal cisterns and the posterior fossa, a CSF-sample was 
collected with a pre- cut baby-feeding catheter #6, connected to a 10 ml syringe. The 
catheter was placed below the tentorium via the tentorial slit and fluid was aspirated 
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gently from the posterior fossa. The collected CSF was transferred to centrifuge tubes 
and processed in an identical manner to the cyst fluid.  
3.5 Sample handling  
The samples were transferred to polypropylene tubes (Nunc CryoTube, Thermo-
Fischer Scientific, Roskilde, Denmark) and centrifuged for five minutes at 450 x g to 
remove cells and cell debris. The supernatant was transferred to new polypropylene 
tubes and immediately stored on dry ice prior to long term storage at -80°C. Such 
sample handling has previously been demonstrated to reduce degradation of 
components and lysis of cells in centrifugation precipitate, which may change the 
composition of the sample [68].  
3.6 Chemical analysis  
Analysis of the AC fluid and CSF for Paper I were performed at the Laboratory for 
Clinical Biochemistry, Haukeland University Hospital. The laboratory is accredited by 
Norwegian Accreditation (accreditation number “TEST 231”) as a testing laboratory 
and complies with the requirements of NS-EN ISO 15189. Clinical chemistry analysis 
was performed on a Modular Analytics System by Roche Diagnostics (Roche 
Diagnostics GmbH, Mannheim, Germany), except for osmolarity, which was 
measured by freeze point depression on a Fiske Micro-Osmometer (Fiske Associates, 
Massachusetts, USA) and immunoglobulins, which were measured by nephelometry 
with system specific N antisera to Human Immunoglobulins (Dade Behring Marburg 
GmbH, Marburg, Germany) on a BN Pro Spec System (Siemens Healthcare 
Diagnostics, Illinois, USA).  
 
 50
3.7 Qualitative proteomics 
The qualitative proteomics for Paper II was performed as two experiments of several 
sequential steps. The quantitative data in paper III provides information on qualitative 
identities on identified proteins. In paper II, the first part is an evaluation of the 
similarity in the qualitative proteome between the individual patients included. The 
second part is an evaluation of a pool of a selection of the same patients.  
 
The protein concentration in AC fluid was measured using a QubitTM, a step 
necessary to control the amount of protein in each sample. This is a method using dye 
to bind protein and measure the concentration on basis of ultraviolet spectrometry 
versus a calibration curve. AC fluid was concentrated and desalted using molecular 
weight cut-off filters and the solvent was removed in a vacuum concentrator. The 
amount of protein from each patient was standardised to avoid the introduction of 
variance in the data set. 
 
The proteins were digested into peptides using laboratory trypsin protocols [121]. For 
the second experiment, the peptides were fractionated by SCX chromatography to 28 
fractions and vacuum concentrated to dryness after thorough preparation through 
desalting. 
 
In the first part of Paper II, the AC protein comparison experiment, the peptides were 
prepared for and analyzed by a nano-HPLC coupled to an ion trap mass spectrometer.  
Data were collected in automatic MS-MS-mode. The raw data was processed with the 
Spectrum Mill search engine. Peptide and protein identifications were accepted when 
the probability of correct identification was greater than 95 %, with a minimum of two 
identified peptides per protein. 
 51
 
The statistical analysis for evaluating similarity was performed by principal 
component analysis [122]. Models for this analysis were made both for all proteins 
and for the 50 most prominent proteins in order to reduce the probability of proteins 
near the detection limit to introduce noise to the dataset. The intent of this approach 
was to evaluate statistical outliers. Furthermore, a sub-sampling scheme was 
performed where 50 proteins were drawn on random to build a model, evaluating the 
stability of the dataset – a design made to reveal if any particular sample would cause 
divergence in data. [123, 124]. Statistics was performed in the statistical software 
package R. 
 
For the second part of Paper II, the AC proteome evaluation experiment, the separate 
fractions from the SCX fractionation of peptides were prepared and analyzed by a 
nano-HPLC system coupled to an ESI-Q-TOF mass spectrometer.  
 
To reduce false positive proteins reported specifically for AC fluid, a supplementary 
experiment was performed, where supposedly selective proteins for AC were searched 
for by targeted proteomics. We used the MIDAS workflow (Multiple Reaction 
Monitoring (MRM) initiated detection and sequence analysis) [125] as hypothesis 
driven proteomics increase the sensitivity for specific proteins. MIDAS is a method 
selecting the mass spectrometer to look only for specific predicted masses from 
peptides, thereby increasing sensitivity in the instrument. These analyses were 
performed on a nano-HPLC system coupled to a Q-TRAP 5500 mass spectrometer. 
Data was extracted with Masslynx, merged utilizing PklFileMerger [126]. MS/MS 
data were searched using the MASCOT software platform against the IPI-human 
database [127]. Protein organization and redundancy reduction was done using the 
Scaffold software [128]. Peptide and protein identifications were accepted when the 
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probability of correct identification was greater than 95 %, with a minimum of two 
identified peptides per protein.  
 
The protein list resulting from these experiments was compared with published 
proteome libraries of CSF [129] and plasma [130]. Database comparison, as well as 
information about protein functional characteristics, was performed using 
ProteinCenter with mappings from the Gene Ontology Consortium website [131].  
3.8 Quantitative proteomics.  
In Paper III we performed two semi-quantiative experiments, one using a label-free 
global shotgun approach on individual patient samples, and one approach based on a 
pool of several samples quantified using an iTRAQ approach combined with extensive 
fractionation. 
The individual label-free quantitation experiments were performed by LC-MS on 
samples subjected to in solution digestion [121]. The peptide mixture was separated by 
reverse phase C18 chromatography, then transferred by electrospray and analyzed by 
the LTQ-Orbitrap Velos Pro. The resulting data was searched against the SwissProt 
database using SearchGUI with OMSSA and XTandem as search engines and 
PeptideShaker [132] for combining the results. Progenesis LC-MS (Nonlinear 
Dynamics Ltd. Newcastle upon Tyne, UK) was used in the data analysis. 
 
The iTRAQ-labelled quantification experiment was performed on a sample-mix 
depleted of high abundant proteins by a Multiple Affinity Removal System (MARS 
hu-14) (Agilent Technologies), removing the 14 most abundant proteins in the samples 
by immuno depletion to increase the dynamic range of the experiment and the 
sensitivity for detection of low-abundant proteins. The samples were digested by 
trypsin [121], and then labelled by iTRAQ chemical labelling according to 
manufacturers protocol with a mixture of the two samples as control. The mixture of 
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labelled AC fluid, the CSF and the 50:50 control sample were combined as iTRAQ-
labelled peptides. To increase the proteome coverage, the samples were fractionated 
into 28 fractions using mix-phase (RP-WAX) chromatograpy. This is a method 
combining the chemical properties in reverse phase chromatography and ion exchange 
chromatograpy.  The samples were analyzed by LTQ-orbitrap Velos Pro mass 
spectrometry coupled to an on-line nano-HPLC in the similar manner as the label-free 
experiment, using HCD instead of CID as method for collision cell. The resulting data 
was searched against the SwissProtKB database using using the Spectrum Mill 
software package (Agilent Technologies, Santa Clara, CA).  
3.9 Statistical methods 
Principal component analysis (PCA) is a workhorse in complex statistical analysis 
with more than one variable. The principle of PCA is to create arbitrary 
multidimensional vectors through the dataset, where the first vector explains as much 
as possible of the variance in the dataset. The second vector orthogonal to the first 
vector and explains the remaining variance in the dataset after the first vector is 
explained. The data are projected down on the new vectors as arbitrary axes, 
supplementing the original axes. This is a way to handle variation across multiple axes 
without knowing the degree of independence in the dataset. 
 
False Discovery rate (FDR) is a statistical method to handle multiple testing problems 
[133, 134]. FDR determines the amount of false discoveries in a dataset, such as the 
erroneous reporting of a protein being present. Most instrument packages for the 
analysis of mass spectrometry reporting data have a cut-off at around 1.0 %, implying 
that not more than 1.0 % of the reported proteins are erroneously identified. 
 
Bonferroni correction [135] is a way to handle the problems of multiple testing, 
correcting for false positives only. The Bonferroni correction divides the p-value 
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limitation on the number of tests, thus increasing the significance needed when testing 
for multiple tests. As a method, this is considered extremely conservative.  
3.10 Databases 
The International Protein Index (IPI) [136] has been common database for searching 
mass spectrometry data using search algoritms like Spectrum Mill and Mascot. The IPI 
database of protein identities is currently on the verge of being discontinued, and 
UniProtKB is currently the most used database. This is a more specific and stringent 
database. The UniProtKB/Swissprot database is a high-quality register of protein, 
manually reviewed by experts and is the current consensus database for reporting of 
protein identities. The UniProtKB is developed by a consortium consisting of the 
European Bioinformatics Institute, the Swiss Bioinformatics Institute and the Protein 
Information Resource, supported by US and EU funding. We used IPI human in Paper 
II and UniProtKB in Paper III. 
 
Proteins with increased or reduced abundance between CSF and AC fluid in both label 
free and iTRAQ labelled experiment from paper III were compared to the mRNA 
microarray results previously published using J-Express Pro (*'$) < -" )<
*-24).  
 
Gene ontology data for the identified proteins in the mapping experiment in Paper II 
and the iTRAQ experiment in paper III was obtained using ProteinCenter (Thermo-
Fischer scientific, Odense, Denmark). 
3.11 Synopsis of results: 
In Paper I, we found that AC fluid and CSF had the same osmolarity. We did not find 
any significant differences in the concentrations of sodium, potassium, chloride, 
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calcium, magnesium or glucose. The concentration of phosphate was significantly 
elevated in AC fluid (0.39 versus 0.35 mmol/L in CSF; p = 0.02), whereas 
concentrations of total protein (0.30 versus 0.41 g/L; p = 0.004), ferritin (7.8 versus 
25.5 ug/L; p = 0.001) and lactate dehydrogenase (17.9 versus 35.6 U/L; p = 0.002) 
were significantly reduced in AC fluid relative to CSF. Based on these observations 
we concluded that AC fluid is not identical to CSF. The differential composition of 
AC fluid relative to CSF supports secretion or active transport as the most probable 
mechanism underlying cyst filling. Oncotic pressure gradients or slit-valves as 
mechanisms for generating fluid in temporal ACs are not supported by these results.  
 
In Paper II, we did not identify systematic trends or grouping of data, implying low 
variability between individual proteomic profiles of AC. 
In a pool from 11 patients, we identified 199 proteins. The identified proteins, as well 
as supplementary MIDAS experiment, show a high similarity in protein profiles 
(192/199) between AC and CSF, as well as a considerably lower similarity towards 
plasma. The high qualitative overlap gives an indication that CSF should be somewhat 
involved in the mechanisms for filling and sustaining of such cysts. This was the first 
evaluation of arachnoid cysts by proteomics. 
 
In Paper III, we quantified 348 proteins to obtain an abundance ratio between AC fluid 
and CSF proteins in these samples collected from five individual patients. In a pool 
from the same patients in depleted and fractionated samples, we quantified 1425 
proteins between AC fluid and CSF. 296 proteins were identified in common in both 
individual and fractionated depleted pooled samples.  
In the individual samples, based on strict identification criteria (2 peptides, 95 % 
peptide and protein confidence, FDR <1.0 %), 150 protein groups (43 %) (of which 
133 also were identified from the iTRAQ experiment) were identified as significantly 
different between the two groups by paired two-sided t-test on 95 % confidence. From 
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the differentially abundant proteins, 22 proteins had a fold change of >1,5 (log2 = 
0,58) in both individual label-free average as well as in iTRAQ-labelled samples, 
while 24 proteins had a fold change of <0,67 (log2 = -0,58) in both the label-free 
experiment on individual patients and in iTRAQ experiment performed with pooled 
samples. This finding supports our previous claim that AC fluid is different from CSF.       
 
We did not quantify any of the proteins associated to genes previously mentioned as 
regulated in relation to AC [43, 46]. Searching mRNA microarray data [46] against 
our proteins with change in abundance do not show a strong correlation – an 
observation we attribute to membrane proteins not necessarily present in liquid phase 
due to the hydrophobic nature of membrane proteins.  Our data from quantified 
proteins did not support the previously suggested gradient in molecular weight over 
the AC membrane.  
3.12 Discussion 
The scope of this thesis has been to gain further insight in the mechanisms for filling 
and sustaining of AC. This is a topic where basal research is scarce. Rengachary et al 
[27, 28] analysed membranes of AC by histology and electron microscopy. Interesting 
findings in these studies is of a single-layer covering of AC by mesotelial cells, the 
absence of inflammatory cells and the unusual presence of clear arachnoid cells 
resembling fetal arachnoid cells. Schachenmayr and Fride [31] point at a layer of 
extremely flattened cells lining the arachnoid membrane. Sandberg et al [42] 
performed chemical analyses in AC fluid, reporting similar values as expected for 
reference CSF. Helland et al [43] and Aarhus et al [46] identified slight differences in 
DNA microsatellites and mRNA microarray of membranes of AC relative to control 
arachnoid membrane. The nature and mechanisms of the splitting and change of 
structure of AC membrane, as well as the content and composition of AC fluid, is still 
unclear. This was the basis on which the studies were undertaken. 
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In our studies, we find that AC fluid is different from CSF both evaluated by clinical 
chemistry and by quantitative proteomics. Our observation that the protein 
concentration is lower in AC fluid relative to CSF is not consistent with the suggested 
mechanism of oncotic pressure. The hypothesis in oncotic pressure mechanism is that 
proteins bind salts, increasing osmotic pressure binding water. The most known 
mechanism of oncotic pressure is the role of albumin in the blood system. A reduced 
protein concentration is thus not consistent with such findings. We find a reproducible 
difference in concentration between the individual patients, as well as low blood 
signatures. We interpret this as a stable difference and relatively safe as a conclusion 
in the current studies.  
 
The qualitative proteomics data show a large degree of similarity of AC fluid relative 
to CSF, while larger differences to that of plasma. This is a relatively simple 
comparison, but it clarifies both that the similarity to CSF is present, judging by the 
difference to plasma. The comparison between the individual samples, using our 
known deviating samples as internal controls demonstrate consistent results in the 
content of individual cysts. Paper II was the first proteomics analysis of AC while 
Paper III is the largest.  
 
The quantitative proteomics performed by both global shotgun label-free proteomics 
and iTRAQ chemical labelling after extensive fractionation is relatively sophisticated 
as methodology. The proteins reported as altered in abundance in these studies are 
only the ones being consistently different in both label-free and iTRAQ-labelled 
samples. In the methodology applied, we tried to correct for the possibility of single 
outliers in individiual experiment using the t-test. The significance criteria are 
probably too stringent. With large resources, reducing the significance criteria and 
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introducing verification steps, this experiment could yield reports with higher 
confidence.  
 
3.12.1 Paper I:  
The scope of this paper [137] is relatively simple; to characterise AC fluid and CSF by 
clinical chemistry. The samples were collected and handled in accordance with a 
standardised protocol, and stored in an ultra freezer at -80oC until analysis, and 
analysed at the same time in an accredited hospital laboratory.  
The rationale for this paper was that there are three prevailing theories for the filling of 
AC. Go et al [38] suggested in 1984 that the presence of transport ATPase in the 
luminal cell membrane of AC could be interpreted as evidence of an active transport 
mechanism. Dyck and Gruskin [39] suggested in 1977 that filling of cysts could 
happen by osmotic gradients such as xantochromia after a previous hemorrhage. Smith 
and Smith [40] suggested a ball-valve mechanism for trapping of fluid, causing the 
cyst to expand. Santamarta et al [41] claim to have observed a slit valve in 
preoperative MRI for such a cyst. Such valves have however only been observed 
intraoperatively in suprasellar AC and not in temporal cysts. 
 
These different mechanisms of filling of AC would be expected to cause different 
clinical chemical profiles. Osmotic gradients would necessarily demand a higher 
osmolarity inside the cyst, perhaps also equal, as the cyst may have reached 
equilibrium. To create this osmotic gradient, elevated protein content would be 
needed. Slit valves would probably cause some sort of skewed distribution of ions, as 
one would expect some sort of general up-concentration while some water and ions 
might be resorbed or leak. A mechanism of active transport might cause a skewed 
distribution of some, but not all ions, depending of the type of transporter.  
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The results in this paper did not show significant changes in most electrolytes except 
for phosphate, which is 1,11 times higher in AC. The distribution of larger proteins as 
measured by clinical chemistry was interesting as a scientific finding. The possibility 
of a decreasing gradient of proteins dependant on protein molecular weight in AC 
relative to CSF is a finding that cannot be attributed to possible blood contamination in 
CSF. This might imply some kind of unknown protein selectivity. However an 
interesting hypothesis, we later refuted it in Paper III. The finding that protein 
concentration is lower in AC did not support an oncotic pressure mechanism, where 
proteins bind up electrolytes creating an osmotic pressure – the same mechanism as 
that of albumin in plasma.  
 
Concerning the technical set-up for this experiment and future improvements, 
performing sample collection with a small aliquot set aside and analyzed by cell-
counter, would give information on the cells and debris now precipitated away before 
freezing. In a new set-up like this, more analytes could probably be included. The 
possibility of including more patients might as well increase the significance of this 
study, perhaps also with a more thorough control with factors such as previous 
operations, bleeding in close proximity or other cases useful for evaluating and 
differentiating the primary from the secondary arachnoid cysts [13].  
 
3.12.2 Paper II:  
The scope of this paper [138] was to explore the nature of the content of AC by 
proteomics, evaluated by qualitative proteomics. The sample material for these studies 
origins from the same patients as for the clinical chemistry study. This study was 
exploratory in nature; to our knowledge there are no similar studies on AC.  
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The qualitative proteome of AC was relatively similar to that of normal CSF, but not 
to that of plasma. As a simple observation, if the mechanism is due to active secretion, 
either the mechanisms have to be like that of CSF-production in the choroid plexus as 
is not observed in microscopy studies, or there is a mechanism transporting some 
components from CSF to AC fluid. The qualitative profiles of individual AC show a 
high similarity to each other, a finding supportive of but not conclusive, that primary 
AC is a unique condition.  
 
Concerning the selection criteria for the second part of article II, we did not have a 
good prior scientific foundation on which patient’s samples to include or exclude in 
the studies. We excluded samples with detected content of blood proteins, as well as 
the two patients previously either operated or with a prior bleeding in close proximity 
to the AC.  
 
From the analysis of AC fluid versus CSF, we also found the similarity so high that we 
suggested quantitative strategy as more appropriate for evaluating AC by proteomics, 
as were performed in Paper III. 
 
3.12.3 Paper III. 
The scope of Paper III [submitted] was to compare AC fluid and CSF, with high 
qualitative similarity as observed in Paper II, by quantitative measures. The concept is 
that even though the same proteins are identified, quantitative differences in proteins 
may represent a change in function as proteins perform a multitude of cellular and 
biologic functions. Furthermore, we wanted to link the results from this experiment 
against prior research on AC, in particular the mRNA microarray data in Aarhus et al 
[46].  
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For proteomic data, this is a study where the number of patients is low (n=5). 
Furthermore, the labelled quantitative proteomic data is performed as a single 
experiment in a pool of the same patients. We did not perform external validation, 
such as selective reaction monitoring (SRM). Proteomic results are constructed as 
layered probabilistic statistics, where mass spectrum data are annotated to peptides and 
peptides to protein groups. Annotation as protein groups instead of single proteins is 
an effect of shared peptides between different versions of the same protein, where the 
post-translational modification (PTM) is not a part of the peptide identified [139]. 
 
Comparing quantitative data of a multitude of proteins with probable partial co-
variation calls for sober use of significance criteria. In the experiment of label-free 
individual samples, 150 of 348 protein groups (43 %) were significant as different in 
abundance in a two-sided paired t-test, treated individually. A problem to be handled is 
the fact that this is in principle multiple testing. In a normally distributed population, 
one would expect 5 % of the samples to be reported as significant, implicit in the 
p=0,05. Bonferroni correction of results is in general considered too stringent for such 
a purpose [140]. False Discovery Rate [133, 134] is currently used to determine a cut-
off on the number of protein groups reported, to reduce the probability of reporting 
proteins findings not present. Reproduction of results by different modalities, in 
instrumental and biologic replicates, as well as external validation, are good strategies 
to confirm that a differential abundance of a protein group is in fact explained by 
biology, rather than being an analytical error. 
 
In the CNS, and in particular CSF, blood contamination is a great risk factor for false 
reporting of findings. This is due to the fact that the protein concentration in CSF is 
0,5-1 % of that of blood/plasma. In the CSF, 80 % of the amount proteins are blood-
derived and blood contamination will skew the distribution of proteins in CSF relative 
to any other liquid medium in the CNS, such as AC fluid. The AC fluid collected in 
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this experimental set-up was relatively safe from blood contamination. The CSF will, 
no matter the rigidity in collection, contain a minute amount of blood.  
 
Comparing the mRNA microarray data against our proteins with change in abundance 
did not show a strong correlation – an observation we attribute to membrane proteins 
not necessarily present in liquid phase due to the hydrophobic nature of membrane 
proteins. As a research hypothesis, this is still an interesting question. Performing 
proteomics on AC membranes could be a strategy for evaluating active transport by 
membrane proteins. A challenge in this particular set-up will be the same as in this 
paper, the need for adequate controls. Presumably arachnoid membranes from the 
same individual outside the cyst could be used with the patient as his own control, but 
no method with acceptable and feasible sampling has been devised.  
 
Our data did not support a gradient in molecular weight from quantified proteins 
previously suggested. The observation on clinical chemistry in AC fluid compared to 
CSF in Paper I was tested by plotting the fold change between proteins in AC fluid 
and CSF against the molecular weight of the proteins. There was no correlation in this 
plot, a finding that supports rejection of the molecular weight gradient hypothesis. 
 
3.12.4 Methodological considerations 
In the process of science, an increased insight into the potential for better research is 
quite common, as it has been in this project as well. A first observation is that the 
collection of high-quality samples is a challenge in a clinical and intraoperative 
setting. Firstly, since the surgeon or clinician collecting the samples and the person 
handling the sample are not the same person, the information transfer on a synopsis of 
previous medical history could be improved before making the samples anonymous.  
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Second, during the collection of CSF in the basal cisterns the risk of minute amounts 
of blood mixing with the CSF is present. During sample collection, blood 
contamination of samples is a problem since it is difficult to control. This was not the 
case for the AC fluid, collection methods has been relatively controlled. Puncture of 
the AC with a needle, using the pressure measurement device (a CSF manometer) as 
siphon, the collection of AC fluid is not very prone for blood contamination. CSF was 
collected from the bottom of the operative field after complete hemostasis before field 
closure. CSF was aspired through a small plastic tube, a baby feeding tube modified 
by cutting the end for having a flat hole, held by operative forceps under the 
microscope and carefully aspired manually by a syringe. Although observably clean, 
this fresh collected CSF might contain blood and the blood content will not necessarily 
be identical between individuals. As CSF contains 0,3-1 % of the protein content of 
serum, a miniscule contamination of blood will introduce a change in the proteome 
composition. Currently, visual inspection of the pellet after centrifugation has been the 
easiest way to estimate the presence of blood contamination, even if the sample 
appears clear before centrifugation. For future sample collections, saving a small 
aliquot for cell differential counting and perhaps a serum/plasma sample as well for 
future reference could increase the sample quality.  
 
Third, the development and improvement in methodology for proteomics is clear for 
such a project as ours, where in Paper II, we identify 199 proteins by qualitative 
measures after fractionation, while in Paper III, we identify 1425 in one experiment 
while utilizing a more stringent databases and search criteria. This is in part the 
availability of MARS-14 abundant protein depletion, the improved fractionation of 
mix-phase columns and especially the use of a modern Orbitrap instrument replacing 
an elderly qTOF instrument. 
 
Fourth, patient selection could in our material include more information on past 
medical history before anonymisation. As the responsible surgeon and the persons 
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handling the samples is not the same, there might be better information transfer 
possible. Still, this is a balance on the definition of what is anonymous, and was not 
specified in the informed consent. Exclusion criteria were therefore relatively simple. 
 
Fifth, the comparison of mRNA from membranes of the same patients as were 
operated, as well as possible control from the same patients, could reduce the 
biological variation in our comparison. 
 
Sixth, the statistics applied is not ideal, seen from a statistician’s perspective. This is a 
consistent problem in proteomics, where methods are developing along with the 
technical and methodological progress of the field in general. Currently, there are 
consensus criteria on what constitute a real difference in datasets such as the ones 
applied, but neither the limitations nor the results are cut in stone.  
 
3.12.5 Future perspectives 
In the perspective for future research on AC, the arachnoid cells lining the cavity of 
the AC would be very interesting for targeted proteomics approaches. There have been 
some studies in this direction, Schachenmayr and Friede did not identify pinocytotic 
vesicles in the membranes, using this as argument against transcellular active transport 
[31]. Later, with the recognition of other transport mechanisms, some attempts to 
demonstrate aquaporins in the AC membrane have failed [141]. The salt pump 
NKCC1 [43] is currently the most interesting mechanism suggested, but needs 
verification in larger datasets. Targeted searches against molecular machinery by 
proteomics may identify the presence of active pumps in the inner membranes. The 
possibility of analysing AC membrane and normal arachnoid membrane from the same 
patients would probably be an alternative strategy if we disregard current resources 
and availability of sample material.   
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4. Conclusions 
4.1 Main objectives: 
We have characterised AC fluid by clinical chemistry and proteomics. The AC fluid 
and CSF is very similar, but not identical. The reduced protein concentration in AC 
fluid relative to CSF does not support oncotic pressure as a mechanism of filling and 
sustaining of arachnoid cysts. Differences in both total and individual protein 
abundance do not support a valve as a filling mechanism. From our data, we believe 
some kind of active transport to be the most plausible of the three mentioned 
mechanisms for filling of AC. 
 
Paper II was the first proteomics evaluation of AC fluid, while Paper III is the first 
quantitative proteomics paper on AC fluid versus CSF and the largest qualitative 
characterization of AC fluid. 
4.2 Secondary objectives: 
1. The clinical chemistry between AC fluid and CSF show high similarity between 
the two fluids, but protein concentration to be reduced in AC fluid relative to 
CSF, while the phosphate is elevated.  
2. The evaluation of the qualitative proteome of AC fluid show a high similarity 
between individual patients, this as an indication of AC being the same 
condition. There is a high similarity to reference CSF databases and a reduced 
similarity relative to plasma reference databases. This is indicative for CSF to 
have some involvement in the filling mechanism of AC. 
3. The quantitative proteomics evaluation was performed as two different 
experiments; a labelfree .#*/"0)++-*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Appendix 
Consent form in Norwegian.  
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Nevroklinikken 
Nevrokirurgisk avdeling 
 
Forespørsel om å få oppbevare vev i biobank for forskning 
 
 
Til pasienten 
Du er nå innlagt for å bli operert, og vi ønsker ditt samtykke til at noe av vevet som fjernes 
kan oppbevares i en biobank og brukes til forskning. 
Du mottar denne forespørselen fordi du har fått diagnostisert en cyste i hjernens 
spindelvevshinne (araknoidal cyste). Din identitet blir ikke lagt inn i forskningsregisteret før 
du eventuelt samtykker ved å signere denne forespørselen. 
Hvorfor oppbevare og bruke vev til forskning? 
Det cystevevet som ikke trengs for å stille diagnosen blir vanligvis kastet. I stedet for å kaste 
dette vevet vil vi gjerne bruke noe av det til forskning. Cystevevet og en blodprøve er frosset 
ned. Det vil bli undersøkt på forskjellige proteiner og på arvestoffet (DNA) i både 
cysteveggen og i cystevæsken. Resultatene får ingen konsekvenser for deg, men kan på sikt 
gi oss nye opplysninger om hvordan slike cyster oppstår og skal behandles. Slik kan du 
bidra til å hjelpe pasienter i fremtiden.   
Hvilke opplysninger innhentes om pasienten og hvordan blir opplysningene brukt? 
Vevet i biobanken merkes med et kodenummer for pasienten, slik at data om pasientens 
kjønn, alder, diagnose og behandlingsforløp kan skaffes fra sykehusets pasientjournal og 
røntgenarkiv. Disse blir sammenholdt med vevet i biobanken. 
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Resultater blir publisert i medisinske tidsskrifter, men ikke presentert slik at pasienter kan 
gjenkjennes. Opplysningene lagres i et elektronisk register sammen med et kodenummer. 
Registeret er lagt på en egen forskningsserver på Haukeland Universitetssykehus, i.h.t. 
Helse Bergens rutiner for datasikkerhet. Alle med tilgang har taushetsplikt og behandler 
informasjonen konfidensielt. Registeret er tidsavgrenset, og alt vev destrueres og 
analyseresultater slettes når prosjektet er ferdig, senest i 2100. Prøver kan bli sendt til 
analyse hos forskningspartnere i utlandet, men personopplysninger blir ikke utlevert. 
Hvilke rettigheter har du som pasient? 
Samtykket er helt frivillig, og du tar den betenkningstid du trenger. Har du spørsmål som er 
ubesvart i dette skrivet kan du få snakke med lege eller sykepleier tilknyttet prosjektet. 
Hvorvidt du samtykker har ingen konsekvenser for behandlingen eller forholdet til 
behandlere og andre. Du kan når som helst trekke samtykket tilbake, uten å måtte begrunne 
dette. Vevsprøven blir da destruert, og opplysningene blir slettet fra registeret. 
Informasjonen som inngår i større vitenskapelige arbeider vil ikke kunne trekkes tilbake i 
ettertid. Prosjektet er meldt til Personvernombudet for forskning, Norsk 
samfunnsvitenskapelige datatjeneste og opprettelse av biobank er gjort etter tilråding fra 
Regional Etisk Komite (REK) for Vestlandet og godkjennelse fra sosial- og 
helsedirektoratet. 
Registeret er finansiert av Den Norske kreftforeningen og Universitet i Bergen, og mottar 
ingen støtte fra kommersielle aktører. Ansvarlig for biobanken vil være per Øyvind Enger, 
overlege ved Nevrokirurgisk avdeling på Haukeland Universitetssykehus og forsker ved 
Universitetet i Bergen. 
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Nevroklinikken 
Nevrokirurgisk avdeling 
 
Jeg har mottatt skriftlig og muntlig informasjon, og er villig til å delta i studien og tillater at 
vev oppbevares i biobanken med opplysninger slik det er angitt ovenfor. 
 
______________________________________                                _____________ 
Sign.     Dato 
(Dersom pasient er under 18 år signerer foresatte under for samtykke sammen med 
pasient) 
 
Navn ...................................................................... 
Bruk blokkbokstaver 
Sted..............................................Dato..................... 
 
........................................................................... 
Foresattes underskrift 
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Arachnoid cysts do not contain cerebrospinal
fluid: A comparative chemical analysis of
arachnoid cyst fluid and cerebrospinal fluid in
adults
Magnus Berle1*, Knut G Wester2,3, Rune J Ulvik1,4, Ann C Kroksveen1, Øystein A Haaland5,
Mahmood Amiry-Moghaddam6, Frode S Berven7, Christian A Helland3,2
Abstract
Background: Arachnoid cyst (AC) fluid has not previously been compared with cerebrospinal fluid (CSF) from the
same patient. ACs are commonly referred to as containing “CSF-like fluid”. The objective of this study was to
characterize AC fluid by clinical chemistry and to compare AC fluid to CSF drawn from the same patient. Such
comparative analysis can shed further light on the mechanisms for filling and sustaining of ACs.
Methods: Cyst fluid from 15 adult patients with unilateral temporal AC (9 female, 6 male, age 22-77y) was
compared with CSF from the same patients by clinical chemical analysis.
Results: AC fluid and CSF had the same osmolarity. There were no significant differences in the concentrations of
sodium, potassium, chloride, calcium, magnesium or glucose. We found significant elevated concentration of
phosphate in AC fluid (0.39 versus 0.35 mmol/L in CSF; p = 0.02), and significantly reduced concentrations of total
protein (0.30 versus 0.41 g/L; p = 0.004), of ferritin (7.8 versus 25.5 ug/L; p = 0.001) and of lactate dehydrogenase
(17.9 versus 35.6 U/L; p = 0.002) in AC fluid relative to CSF.
Conclusions: AC fluid is not identical to CSF. The differential composition of AC fluid relative to CSF supports
secretion or active transport as the mechanism underlying cyst filling. Oncotic pressure gradients or slit-valves as
mechanisms for generating fluid in temporal ACs are not supported by these results.
Background
Arachnoid cysts (AC) are relatively common benign
lesions of the arachnoid, with a reported prevalence as
high as 1.1% in the adult population [1]. Clinical presen-
tations of AC include headache, dizziness, seizures [2]
and dyscognition [3]. They can be found all along the
cranio-spinal axis, but have a marked predisposition for
the temporal fossa [4]. The mechanisms underlying the
formation and filling of arachnoid cysts are not well
understood, but clinical, epidemiological, and laboratory
data indicate that genetic mechanisms are involved in
the formation of arachnoid cysts [5,6]. Three prevailing
theories exist for the filling of the cyst: 1) active secre-
tion of fluid by cells in the cyst wall [7,8], 2) fluid influx
due to an oncotic pressure gradient [9], and 3) trapping
of fluid by a valve mechanism [10]. It is conceivable that
the chemical composition of the AC fluid relative to the
cerebrospinal fluid CSF reflects the mechanism by
which the fluid enters the cyst. If the composition is
identical to CSF a valve mechanism appears likely,
whereas if the filling is caused by oncotic pressure, a
higher concentration of proteins in the cyst fluid com-
pared with CSF would be expected. Likewise, cyst fluid
composition could reflect the mechanism of transport
across the cyst wall, if such a mechanism is involved.
In their study of clinical chemical analysis of cyst fluid
in pediatric patients, Sandberg et al. [11] described a
similar chemical composition to that of reference CSF
in the majority of patients investigated, but in 14 of 41
(34%) the protein concentrations were elevated above* Correspondence: magnus.berle@student.uib.no
1Institute of Medicine, University of Bergen, 5021 Bergen, Norway
Berle et al. Cerebrospinal Fluid Research 2010, 7:8
http://www.cerebrospinalfluidresearch.com/content/7/1/8
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© 2010 Berle et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
0.50 g/L in the cyst fluid. Based on these findings, the
authors hypothesized that higher protein content could
contribute to the expansion of the cysts by an oncotic
pressure gradient. We have recently described the up-
regulation of the CSF-secreting cation chloride co-trans-
porter NKCC1 in AC membranes compared with nor-
mal arachnoid [8]. This finding supports fluid secretion
as the main mechanism of fluid accumulation in AC.
The objective of the present study was to analyze the
chemical parameters of AC fluid and compare with CSF
from the same patient, to gain further knowledge of AC
concerning the mechanisms of filling and sustaining of
such cysts.
Methods
Patients
A total of 15 patients (9 female, 6 male, age 22-77) with
unilateral, temporal AC were included. Cyst type and
sidedness are summarized in table 1. Patient 3 had pre-
viously had a chronic subdural hematoma, most prob-
ably caused by the cyst [12]. Patient 4 had undergone
previous surgery for the cyst. The other patients had no
previous history of intracranial hematomas or surgery.
Patients were recruited by written informed consent by
the responsible surgeon. This project was approved by
The Regional Committee for Medical and Health
Research Ethics (REK) of Western Norway (approvals
REK 70.03, NSD 9634 and REK 2009/1885).
Operative technique and fluid sampling
Details for the surgical procedure have previously been
given elsewhere [12-14] but a short description is given
here. All patients were operated with a craniotomy
under general anaesthesia, given as total intravenous
anaesthesia (TIVA) with propofol and remifentanyl.
Vecuronium bromide (Norcuron®) was used as the neu-
romuscular blocking agent. A burr hole was made with
a high-speed drill immediately posterior to the sphenoid
wing in order to gain access to the anterior and most
basal aspects of the middle cranial fossa. The dura and
the underlying cyst membrane were punctured through
the burr-hole with a 23 G, 25 mm long syringe con-
nected to an Optidynamic® spinal fluid manometer
(Mediplast AB, Malmo, Sweden). After pressure equili-
bration and registration, a cyst fluid sample (3 - 5 ml)
was collected using the manometer tube as a siphon.
The sample was immediately transferred to a sterile cen-
trifuge tube for centrifuging and further analytic proces-
sing as described below (sample handling). After this
procedure, a standard craniotomy with a microsurgical
resection and fenestration of the cyst membranes was
performed. Before opening the medial cyst wall and thus
communicating the cyst interior to the basal arachnoid
space/CSF, all cyst fluid was aspirated to avoid cyst fluid
contamination of the CSF.
After opening the medial cyst membrane that covered
the basal structures (the tentorial slit, the oculomotor
nerve, the carotid artery, and the optic nerve), thus
creating communication to the basal cisterns and the
posterior fossa, a CSF-sample was collected with a pre-
cut baby-feeding catheter #6, connected to a 10 ml syr-
inge. The catheter was placed below the tentorium via
the tentorial slit and fluid was aspirated gently from the
posterior fossa. The collected CSF was transferred to
centrifuge tubes and processed in an identical manner
to the cyst fluid.
Sample handling
The samples were transferred to polypropylene tubes
(Nunc CryoTube, Thermo-Fischer Scientific, Roskilde,
Denmark) and centrifuged for five min at 450 x g to
remove cells and cell debris. The supernatant was trans-
ferred to new polypropylene tubes and immediately
stored on dry ice prior to long term storage at -80°C.
Such sample handling has previously been demonstrated
to reduce degradation of components and cell lysis,
which may change the composition of the sample [15].
Samples were thawed for analysis at room temperature
and transferred to pre-marked analysis tubes for labora-
tory analysis.
Chemical analysis
The samples were analyzed at Laboratory for Clinical
Biochemistry, Haukeland University Hospital, 5021, Ber-
gen, Norway. The laboratory is accredited by Norwegian
Accreditation (accreditation number “TEST 231”) as a
Table 1 Characteristics of patients in study with age,
gender, Gallasi-stage [20] and remarks.
Patient Age (yrs),
sex
Side Galassi-stage
[20]
Remarks
1 26, f Left 2
2 43, m Left 2
3 58, f Left 3 Old hematoma
4 34, f Left 2 Reoperation
5 22, f Right 1
6 36, f Right 2 Slight hemolysis
CSF
7 35, f Right 2
8 77, f Left 1
9 42, f Left 1
10 60, m Left 2 Slight hemolysis
CSF
11 56, m Right 2
12 25, m Left 1
13 30, f Left 1
14 37, m Left 2
15 63, m Left 2
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testing laboratory and complies with the requirements
of NS-EN ISO 15189. Clinical chemistry analysis was
performed on a Modular Analytics System by Roche
Diagnostics (Roche Diagnostics GmbH, Mannheim, Ger-
many). The analytical coefficient of variation (CV) is
noted in parenthesis for each analyte; Sodium (CV 1%),
potassium (CV 2%) and chloride (CV 2%), were mea-
sured by ion-selective electrode on an ISE 1800 module.
Magnesium (CV 2.5%), phosphate (CV 3%), calcium
(CV 2%), bilirubin (CV 6%) lactate dehydrogenase
(CV 2.5%), protein (CV 1.8%) glucose (CV 2.5%), trigly-
cerides (CV 3%) and iron (CV 2%) were measured by
photometic assays on a P 800-module. Ferritin (CV 5%)
was measured by an ECLIA (electrochemiluminescence)
immunoassay on an E 170-module. Osmolarity (CV
1.5%) was measured by freeze point depression on a
Fiske Micro-Osmometer (Fiske Associates, Massachu-
setts, USA). Immunoglobulins (CV 2-5%) were mea-
sured by nephelometry with system specific N antisera
to Human Immunoglobulins (Dade Behring Marburg
GmbH, Marburg, Germany) on a BN Pro Spec System
(Siemens Healthcare Diagnostics, Illinois, USA)
Statistical analysis
For each of the thirteen patients without previous
operations or known injuries to the AC, the differences
in concentration between cyst fluid and corresponding
CSF were calculated. A paired T-test was then utilized
to check if the mean ratio was equal to one. Due to
slight hemolysis of two CSF samples (patients 6 and 10),
data from these patients were omitted from the statisti-
cal analyses for lactate dehydrogenase, ferritin and pro-
tein. Two patients (patient 3 and 4) were described
clinically as different from the others, and were com-
pared separately with the thirteen native patients using a
two-sample t-test assuming equal variances. Correlation
between lactate dehydrogenase, ferritin and protein was
determined by correlation analysis as a control against a
possible contamination of the samples with blood.
P-values were calculated utilizing Pearson’s product
moment correlation test. Statistical analysis was per-
formed using the statistics software package R version
2.10.1 (The R foundation for Statistical Computing,
Vienna, Austria).
Results
Chemical analysis of AC fluid and CSF, obtained during
elective surgery for arachnoid cysts from 15 patients,
was performed in a routine hospital laboratory. The
results from the measurements are presented in table 2.
There was no significance difference in osmolarity or
concentrations of sodium, potassium, chloride, calcium,
magnesium or glucose between AC fluid and CSF. The
concentration of phosphate was higher in AC fluid rela-
tive to CSF (0.39 versus 0.35 mmol/L; p = 0.02), while
the concentration of total protein (0.30 versus 0.41 g/L;
p = 0.004), lactate dehydrogenase (17.9 versus 35.6 U/L;
p = 0.002) and ferritin (7.8 versus 25.5 ug/L; p = 0.001)
was significantly lower in AC relative to CSF. Bilirubin,
iron, triglycerides and immunoglobulins were below
Table 2 Results of chemical analysis of AC fluid and CSF in the same patients, with units, number of samples in
calculation (n), mean results for AC fluid and CSF with standard error of mean (SEM) and means of AC fluid/CSF ratio.
Unit n Mean AC fluid +/- SEM Mean CSF +/- SEM Mean cyst/CSF
Sodium mmol/L 13 142.23 +/- 2.14 142.08 +/- 2.71 1.00
Potassium mmol/L 13 2.47 +/- 0.04 2.35 +/- 0.07 1.05
Chloride mmol/L 13 121.23 +/- 1.94 120.15 +/- 2.54 1.01
Calcium mmol/L 13 1.07 +/- 0.01 1.03 +/- 0.03 1.04
Magnesium mmol/L 13 1.20 +/-0.01 1.14 +/- 0.03 1.05
Phosphate mmol/L 13 0.39 +/-0.01 0.35 +/- 0.01 1.11*
Glucose mmol/L 13 2.85 +/- 0.09 3.13 +/- 0.11 0.92
Protein g/L 10 0.30 +/-0.03 0.41 +/- 0.04 0.71**
Lactate dehydrogenase U/L 11 17.91 +/- 2.93 35.55 +/- 4.61 0.57**
Ferritin ug/L 11 7.82 +/- 1.00 25.55 +/- 6.20 0.31**
Osmolarity mosmol/L 13 290.15 +/-1.07 290.08 +/- 0.96 1.00
IgG g/L < 1.50 < 1.50
IgA g/L < 0.25 < 0.25
IgM g/L < 0.18 < 0.18
Iron umol/L low low
Triglycerides mmol/L low low
Significance levels are denoted as p < 0.05 (*) and p < 0.01 (**). Data from patients #3 and #4 are excluded as clinical outliers from this table. Data from patients
#6 and #10 were excluded for protein, lactate dehydrogenase and ferritin due to slight hemolysis in the CSF. Patient #12 was excluded from protein
concentration measurement as an extreme statistical outlier.
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quantification limit for analysis setup. Patient 12 was
identified as an extreme outlier for protein measurement
and was excluded from this analysis.
Correlations were calculated between possible blood
contamination parameters ferritin, lactate dehydrogenase
and protein on the CSF samples without observed blood
contamination (n = 11). The correlation between ferritin
and LD was 0.77 (p = 0.006), ferritin and protein was
0.36 (p = 0.312) and lactate dehydrogenase and protein
was 0.34 (p = 0.34). The protein concentrations in the
cyst fluid from the two clinically different patients
(patient 3 and 4, respectively 6.16 g/L (hematoma) and
3.54 g/L (previous operation)) were significantly elevated
relative to the others (p < 10-16).
Discussion
The aim of the present study was to collect information
that may contribute to the understanding of the
mechanism for arachnoid cyst filling. If the cyst were
filled by a simple valve mechanism, which has been
observed in suprasellar cysts, it would be expected that
the composition of the cyst fluid would be identical to
that of CSF. On the other hand, if the filling was caused
by oncotic pressure, one would expect a difference in
osmolarity between the AC fluid and CSF as well as a
higher protein content in the AC. If the underlying
mechanism were active secretion or transport, this
would probably cause a different concentration of
certain molecules or ions depending on the underlying
transport mechanisms. We found an isotonic AC fluid
with a lower protein concentration than in CSF; this is
not consistent with an oncotic pressure filling
mechanism.
Macromolecules such as albumin (67 kDa), ferritin (24
subunits between 19 and 21 kDa, total weight around
450 kDa) and lactate dehydrogenase (tetramer of about
37 kDa, total weight around 140 kDa) would be
expected to pass freely through a slit in the cyst mem-
brane. However, the ratio between cyst fluid and CSF
for these three protein complexes was reduced (depen-
dent on size), from 0.73 for protein (of which 2/3 albu-
min) to 0.31 for ferritin. Our findings are therefore
contradictive of a slit valve mechanism underlying the
filling of temporal AC.
The skewed distribution of phosphate could imply a
selective or active transport of fluid and solutes over the
AC membranes. This is consistent with previous find-
ings of morphological and enzyme ultracytochemical
structures in the wall of arachnoid cysts assumed to be
capable of fluid secretion, as reported by Go et al [7].
Furthermore, our group has recently published evidence
that there are differences between arachnoid cysts and
normal arachnoid tissue in that the Na-K-Cl cotranspor-
ter NKCC1 is up-regulated in arachnoid cysts compared
with normal arachnoid [8], and a small subset genes are
differentially expressed in arachnoid cysts compared
with normal arachnoid tissue [5]. The phosphate level in
the CSF is kept lower than in the blood [16], due to
active transport mechanisms in the choroid plexus
epithelia. Higher phosphate concentration in the cyst
fluid could imply that the cyst epithelium is either not,
or is differentially equipped with transport mechanisms
relative to the choroid plexus. There are several lines
of evidence suggesting that co-transporters such as
GLUT1, MCT1 and NKCC1 have the ability to trans-
port water along with their respective substrates, regard-
less of the osmotic gradients [17].
As we have only studied temporal cysts, we cannot
generalize the assumption of an active transport
mechanism to all ACs. For other locations, other fillings
mechanisms may well exist, such as a slit-valve in supra-
cellar cysts [18,19]. In our study, two patients differed
from the others - one with a previous hematoma in
close proximity to the cyst and one being a reoperation.
The protein levels in the cyst fluid from these patients
were significantly higher than in the rest of the study
group. In their study Sandberg et al [11] found that 14
of the 41 patients had markedly higher protein concen-
trations (above 0.5 g/L) in the cysts; four of those had
extreme values such as the ones we observed. The cause
for some cysts to have a marked elevated protein level is
not well understood, but products from previous bleed-
ing in the cyst may be one explanation. Correlation ana-
lysis between protein, ferritin and lactate dehydrogenase
was performed as a statistical control to rule out blood
contamination as a possible explanation of the protein
content in the CSF. The protein concentration of CSF
relative to plasma is about 0.5-1%; a leak of plasma to
the CSF would introduce a large source of error to the
analysis. If the difference in concentration of protein,
lactate dehydrogenase and ferritin was caused by blood
contamination, the correlation should be expected to be
significant and close to 100%. These correlation results
do not show a strong association between assumed
blood contaminants and the findings, thus not support-
ing blood contamination as explaining variable.
A limitation for this study is the small number of
samples. Applied on such a dataset, the T-test is vulner-
able to outliers such as the excluded patient 12 in pro-
tein concentration (outlier plots not shown).
Nonetheless, our results can support reflections around
the filling mechanisms for arachnoid cysts. As far as the
authors know, this is the first publication of AC fluid
analysis matched with CSF from the same patient.
Conclusions
The chemical composition of AC fluid found in this
study does not support an oncotic pressure or valve
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mechanism as responsible for filling an AC. Due to the
pattern of differences, we postulate that the filling
mechanism for temporal AC is by either a selective or
active transport mechanism or a secretion from the
cyst-lining cells.
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Protein profiling reveals inter-individual protein
homogeneity of arachnoid cyst fluid and high
qualitative similarity to cerebrospinal fluid
Magnus Berle1*, Ann C Kroksveen1,2, Øystein A Haaland3, Thin T Aye2, Jill A Opsahl2, Eystein Oveland4,
Knut Wester5,6, Rune J Ulvik1,7, Christian A Helland5,6 and Frode S Berven2,8
Abstract
Background: The mechanisms behind formation and filling of intracranial arachnoid cysts (AC) are poorly
understood. The aim of this study was to evaluate AC fluid by proteomics to gain further knowledge about ACs.
Two goals were set: 1) Comparison of AC fluid from individual patients to determine whether or not temporal AC
is a homogenous condition; and 2) Evaluate the protein content of a pool of AC fluid from several patients and
qualitatively compare this with published protein lists of cerebrospinal fluid (CSF) and plasma.
Methods: AC fluid from 15 patients with temporal AC was included in this study. In the AC protein comparison
experiment, AC fluid from 14 patients was digested, analyzed by LC-MS/MS using a semi-quantitative label-free
approach and the data were compared by principal component analysis (PCA) to gain knowledge of protein
homogeneity of AC. In the AC proteome evaluation experiment, AC fluid from 11 patients was pooled, digested, and
fractionated by SCX chromatography prior to analysis by LC-MS/MS. Proteins identified were compared to
published databases of proteins identified from CSF and plasma. AC fluid proteins not found in these two
databases were experimentally searched for in lumbar CSF taken from neurologically-normal patients, by a targeted
protein identification approach called MIDAS (Multiple Reaction Monitoring (MRM) initiated detection and
sequence analysis).
Results: We did not identify systematic trends or grouping of data in the AC protein comparison experiment,
implying low variability between individual proteomic profiles of AC.
In the AC proteome evaluation experiment, we identified 199 proteins. When compared to previously published lists
of proteins identified from CSF and plasma, 15 of the AC proteins had not been reported in either of these
datasets. By a targeted protein identification approach, we identified 11 of these 15 proteins in pooled CSF from
neurologically-normal patients, demonstrating that the majority of abundant proteins in AC fluid also can be found
in CSF. Compared to plasma, as many as 104 proteins in AC were not found in the list of 3017 plasma proteins.
Conclusions: Based on the protein content of AC fluid, our data indicate that temporal AC is a homogenous
condition, pointing towards a similar AC filling mechanism for the 14 patients examined. Most of the proteins
identified in AC fluid have been identified in CSF, indicating high similarity in the qualitative protein content of AC
to CSF, whereas this was not the case between AC and plasma. This indicates that AC is filled with a liquid similar
to CSF. As far as we know, this is the first proteomics study that explores the AC fluid proteome.
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Background
Arachnoid cysts (AC) are benign intracranial lesions
with a reported prevalence in the adult population of up
to 1% [1,2]. AC can be found all along the cranio-spinal
axis, but have a marked predilection for the temporal
fossa [3]. Anatomically, ACs are formed by a splitting of
the arachnoid mater (AM) creating a potential space
that when filled with fluid appears as a cyst [4,5]. Tem-
poral ACs are classified according to Galassi et al. [6].
Briefly, a type I cyst is small, biconvex, and located at
the anterior temporal pole. A type II cyst involves the
proximal and intermediate segments of the Sylvian fis-
sure, and a type III cyst involves the entire Sylvian fis-
sure and has often a marked radiological mass effect.
The cyst wall is composed of non-neoplastic arachnoid
cells with a capacity to secrete fluid [7,8] that slightly
differs in chemical composition from that of cerebrosp-
inal fluid (CSF) [9]. The genetic profile of temporal AC
membranes [10] indicates that these cysts represent a
homogenous condition, but the underlying cause of AC
formation is unknown. Further analyses of the cyst fluid
with proteomics, the large-scale studies of proteins,
might give indications of the aetiology of AC and thus
shed further light on the mechanisms underlying fluid
secretion and transport.
One aim of this study was to compare the protein con-
tent of cyst fluid from temporal AC of different individuals
using proteomics (AC protein comparison experiment).
Our hypothesis was that AC is a homogenous condition,
and that we could identify a similar protein profile from
AC from different patients. Homogenous protein content
between AC fluid from different patients would point
towards similar filling mechanisms for the examined
patients. Large differences in some patients would indicate
different filling mechanisms in these patients. Such a dif-
ference, if present, would be revealed by a label-free pro-
teomics comparison approach. Mass spectrometry-based
label-free approaches are commonly used for semi-quanti-
tative comparison of complex protein samples [11].
Another aim of the study was to identify the major
proteins present in AC fluid and examine if these pro-
teins also appeared in CSF and plasma (AC proteome
evaluation experiment). For the proteins that did not
appear in the CSF and plasma protein databases, we
used a targeted mass spectrometry protein identification
approach referred to as MIDAS in an attempt to identify
these AC fluid proteins in CSF. The protein content of
AC fluid is largely unknown, but it has been shown to
have reduced protein content relative to that of CSF
from the same patient, as evaluated by clinical chemistry
[9]. In a similar study, Sandberg et al. [12] studied the
clinical chemistry of AC fluid in pediatric patients. We
did not have specific hypotheses on the degree of simi-
larity of AC fluid to CSF or plasma, as this has not been
thoroughly demonstrated in literature. This AC fluid
protein identification part of our study and comparison
with CSF and plasma might give information about the
origin of the AC fluid and the mechanisms of filling and
sustaining of AC.
Methods
Participants and collection of AC fluid and CSF
15 patients (six male, nine female, age 22-77 y) with
unilateral, temporal AC were included in the study. AC
fluid was collected during surgery for AC at Haukeland
University Hospital (Bergen, Norway). The patients’
characteristics are summarized in Table 1. One patient
(No. 3) had previously been operated for a chronic sub-
dural hematoma, most probably caused by the cyst [13],
and another patient (No. 4) had undergone previous
surgery for the AC. The other patients had no previous
history of intracranial hematomas or surgery. The sam-
ple collection and handling protocol used in this study
have been described in detail elsewhere [9,14]. Briefly,
AC fluid was collected during elective surgery for AC
(craniotomy with fenestration and extirpation of the
cyst) by puncturing the dura with a 23G, 25 mm long
syringe needle using an Optidynamic® spinal fluid man-
ometer (Mediplast AB, Malmo, Sweden) by siphoning
through a burr hole before the craniotomy/opening of
the dura. This procedure ensures that CSF does not
contaminate the collected AC fluid: The remaining fluid
in the cyst was removed by suction during opening of
the cyst wall. The collected AC fluid was centrifuged at
450 × g for 5 min to remove cells and cell debris, and
the supernatant was aliquoted and frozen at -80°C.
Table 1 Table of arachnoid cyst patients in study, with
age/sex, sidedness, Galassi-stage [6] and remarks.
Patient Age (yrs),
sex
Side Galassi-stage
[6]
Remarks
1 26, f Left 2
2 43, m Left 2
3 58, f Left 3 Old haematoma
4 34, f Left 2 Reoperation
5 22, f Right 1
6 36, f Right 2
7 35, f Right 2
8 77, f Left 1
9 42, f Left 1
10 60, m Left 2
11 56, m Right 2
12 25, m Left 1 Slight observed
haemolysis
13 30, f Left 1
14 37, m Left 2
15 63, m Left 2
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Deviations and observations on individual sample mate-
rial were noted on sampling. During this sampling,
slight hemolysis was observed in one patient sample (No
12). The CSF used for the targeted AC protein identifi-
cation experiment was collected under informed consent
as lumbar CSF before spinal anaesthesia in patients
undergoing lower extremity orthopedic surgery from
neurologically healthy individuals. The CSF was handled
by the same protocol as for the AC fluid, and the CSF
used in this experiment was pooled from 11 individuals.
Ethics
Patients were recruited by the responsible surgeon and
signed a written informed consent. This project was
approved by the Regional Committee for Medical and
Health Research Ethics (REK) of Western Norway
(approvals REK 70.03, NSD 9634, REK 151.06 and REK
2009/1885).
Chemicals
Trypsin was purchased from Promega (Fitchburg WI,
USA). Urea, acetonitrile (ACN), formic acid (FA), cal-
cium chloride (CaCl2), iodoacetamide (IAA) and dithio-
threitol (DTT), potassium phosphate monobasic
(KH2PO4), potassium chloride (KCl), water and trifluor-
oacetic acid (TFA) were purchased from Sigma-Aldrich
(St. Louis MO, USA). Water and ACN were of HPLC
quality.
Sample preparation and protein digestion
The protein concentration in AC fluid was measured
using a Qubit™ fluorometer (Life Technologies, Carls-
bad CA, USA). AC fluid was concentrated and desalted
using Amicon 3 kDa molecular weight cut-off filters
(Millipore, Billerica, MA, USA) and dried in a vacuum
concentrator (Eppendorf, Hamburg, Germany). The pro-
teins were digested into peptides using in-solution diges-
tion, as follows: The dried protein pellet was dissolved
in 6 M Urea and 100 mM DTT and incubated for 1 h
at 37°C. Cysteins were alkylated using 200 mM iodoace-
tamide and the samples were incubated for 1 h at 37°C.
Chymotrypsin activity was inhibited by adding 2 mM
CaCl2 the proteins were digested to peptides over night
using a protein:trypsin ratio of 1:50. Each sample was
acidified using 5% TFA to quench the digestion activity,
followed by drying the sample completely in a vacuum
concentrator.
Strong cation exchange (SCX) chromatography
The samples were dissolved in 120 μL of SCX loading
buffer (5 mM KH2PO4, 25% ACN, 0.05% FA, pH = 3)
and fractionated by SCX chromatography using an Ulti-
mate 3000 LC system (Dionex, Ultimate, Sunnyvale, CA,
USA) equipped with a BioBasic SCX column (150 mm
× 2.1 mm, 5 μm, Thermo Scientific, Ontario, Canada).
The peptides were eluted in SCX elution buffer (500
mM KCl, 5 mM KH2PO4, 25% ACN, 0.05% FA, pH 3.0)
over 55 min with a flow rate of 0.2 mL/min. A total of
28 SCX fractions were collected. The first two fractions
(SCX fraction 1 and 2) were collected with 5.5 min
intervals (first 11 min) and the last fraction (fraction
number 28) was collected over the last 5 min. Fractions
number 3-27 was collected with 1.5 min intervals. After
collection, each SCX fraction was vacuum concentrated
to dryness.
Sample clean-up
The samples were desalted using a 96 well reverse phase
Oasis® HLB μElution Plate 30 μm (Waters, Wilford,
MA, USA). The wells in the μElution plate were condi-
tioned with solvent B (80% ACN, 0.1% FA) and there-
after washed twice with solvent A (0.1% FA). The
peptides were re-suspended in solvent A, added to the
μElution plate, and washed thrice with solvent A before
the peptides were eluted twice using solvent B. One-
minute centrifugation at 200 × g was used for all centri-
fugation steps except for addition of sample where 3
min at 150 × g was used. The samples were concen-
trated to dryness under vacuum and frozen at -80°C
prior to mass spectrometry (MS) analysis.
Mass spectrometry
In the AC protein comparison experiment, the peptides
were dissolved in 0.1% FA, and 4 μL (1.6 μg) of the
sample was injected onto a 40nL enrichment column
(Zorbax 300SB C18 5 μm, Agilent Technologies, Santa
Clara, CA, USA) at a flow rate of 3 μL/min using 3%
ACN, 0.1% TFA. The separation column (0.0075 × 43
mm Zorbax 300SB C18 5 μm, Agilent Technologies)
was used with the following gradient and a flow rate of
300 nL/min using solvent A (0.1% FA) and solvent B
(90% ACN, 0.1% FA): 3-15% solvent B for 3 min, 15-
45% solvent B for 42 min, 45-90% solvent B for 5 min
and back to 3% solvent B after 5 min. Both columns
were integrated in a CHIP (Agilent Technologies, Santa
Clara, CA, USA), and an 1100 cap/nano HPLC coupled
to a chip-cube-LC/MSD XCT Plus ion trap mass spec-
trometer (Agilent Technologies, Santa Clara, CA, USA)
was used for separation and analysis, respectively. MS
data was acquired using the AutoMS2 mode of the
three precursors with highest intensity active exclusion
for 1 min.
For the AC proteome evaluation experiment, the pep-
tides were dissolved in 0.1% FA and 5 μL of the sample
was injected to the analytical fused-silica capillary col-
umn (15 cm long, 75 μm i.d.) packed with Reprosil-Pur
3 μm C18 resin (Dr. Maisch, Ammerbuch-Entringen,
Germany). The settings for LC were: Trap column: 2%
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ACN, 0.1% FA with a flow rate of 25 μL/min. Analytical
column: solvent A was 0.1% FA and solvent B was 90%
ACN, 0.1% FA. The flow rate was 0.288 μL/min with
the following gradient: 5-12% solvent B for 2 min, 12-
30% solvent B for 48 min, 30-50% solvent B for 20 min,
50-95% solvent B for 1 min and 95% solvent B was kept
constant for 5 min before regeneration of the column
for 24 min. The nano-HPLC system (Dionex, Ultimate,
Sunnyvale, CA, USA) was coupled to an Ultima Global
ESI-Q-TOF mass spectrometer (Waters, Wilford, MA,
USA). The scan area for the MS survey scan was m/z
300-1500 with automatic fragmentation of the three
ions with highest intensity. All the data was acquired in
data dependent mode.
For the targeted AC protein identification experiment,
the tryptic peptides of CSF from neurologically normal
patients were dissolved in 0.1% FA and 1 μL was
injected into the Q-TRAP 5500 (AB Sciex, Foster City,
CA, USA) coupled to a nano-HPLC system (Dionex,
Ultimate, Sunnyvale, CA, USA). The targeted mass spec-
trometry analysis was done using the MIDAS (Multiple
Reaction Monitoring (MRM) initiated detection and
sequence analysis) workflow [15] selecting a minimum
of 3 peptides per protein, and three transitions per pep-
tide based on information from in silico digestion. The
instrument settings were 15 ms dwell time with approxi-
mately 3.5 s cycle time for 100 transitions per method in
four analyses. MRM was then used as a survey scan in
information dependent acquisition (IDA) to detect spe-
cific peptide peaks, and each resulting MRM peak was
examined by two full MS/MS-scans to obtain sequence
verification of the hypothesized peptide.
Mass spectrometry data analysis
For the AC protein comparison experiment, the raw data
was processed with the Spectrum Mill search engine
(Rev A.03.03.084) (Agilent Technologies, Santa Clara,
CA, USA) using Carbamidomethylation (C) as fixed
modification. The precursor mass tolerance was set to
2.5 Da with a product mass tolerance of 0.7 Da, and
two trypsin miss-cleavages were allowed. The default
autovalidation settings were applied for both protein
and peptide level validation. Briefly, peptides were
accepted at charge +2 if score >11 and%SPI >60 and at
charge +3 if score >13 and%SPI >70. Proteins with a
score >20 were accepted. A threshold of 2 was set both
for peptides and proteins for the forward-reverse score
and the rank 1-2 score, except for charge +2 with score
>6 and%SPI > 90 where the threshold was 1.
For the AC proteome evaluation experiment, the mass
list was extracted into PKL files with Masslynx (Waters,
Wilford, MA, USA) and the PKL files were merged into
a single MGF file using PklFileMerger [16]. All MS/MS
data were searched using the MASCOT (version 2.2.2)
software platform (Matrix Science, London, UK) against
the IPI-human database (v3.69, 174784 entries). Missed
cleavages were set to one using trypsin as the enzyme.
Carbamidomethyl (C) was set as fixed modification
whereas Oxidation (M) was set as variable modifications.
The peptide tolerance was set to 40 ppm and the MS/
MS tolerance was set to 0.6 Da. Protein organization
and redundancy reduction was done using the Scaffold
software (v3.00.02 [17]). Peptide and protein identifica-
tions were accepted when the probability of correct
identification was greater than 95%, with a minimum of
two identified peptides per protein.
To verify peptide specificity in designated protein tar-
gets in the targeted AC protein identification experiment,
MS/MS spectra were extracted using Analyst software
(version 1.5) (Life Technologies, Carlsbad CA, USA).
The selected spectra were searched using the MASCOT
(version 2.3.0) software platform (Matrix Science)
against the IPI-human database (version 3.78, 302626
entries) using precursor mass and MS/MS tolerance at
0.2 Da. Carbamidomethyl (C) was set as fixed modifica-
tion and 0 miss cleavages were chosen.
The protein list from the AC fluid pool created in the
AC proteome evaluation experiment was compared to
published proteome libraries of CSF [18] and plasma
[19]. Database comparison was performed using Protein-
Center, v3.2.0.9 (Proxeon, Odense, Denmark). The
grouping of proteins and analysis of molecular function
and biological processes was performed in ProteinCen-
ter, where gene ontology terms linked to specific pro-
teins are obtained using mappings from the Gene
Ontology Consortium website [20].
Statistical methods
Principal component analysis (PCA) is a mathematical
method that transforms a number of possibly correlated
variables into a smaller number of uncorrelated variables
called principal components, with the objective of
improved understanding of the data [21]. The algorithm
of PCA gives the weight of each principal component,
meaning the percentage of variation in the dataset
explained. In the AC protein comparison experiment, the
protein content between individual samples was com-
pared based on spectral intensities. The spectral intensi-
ties in each sample were normalized based on the total
sum of all intensities in that sample relative to a chosen
reference samples. The protein hits from the AC protein
comparison experiment were sorted according to protein
score. To check for possible outliers, we first did a PCA
including all identified proteins in the analysis, and
plotted the patients according to the two first principal
components. Next, we compared the samples based on
the 50 proteins with highest protein score to avoid large
influence from proteins identified in a low number of
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samples. Finally, we used a sub-sampling scheme [22,23]
consisting of two steps:
1 - select 50 proteins at random and measure the dis-
tance normalized to standard deviation from the origin
of each patient and 2 - repeat the first step 1000 times,
and calculate the average distance from the origin over
the 1000 replications.
This analysis was designed to reveal the degree to
which any particular sample is divergent from the rest.
Statistics was performed in the statistical software pack-
age R, version 2.11.1. (The R Foundation for Statistical
Computing, Vienna, Austria).
Results
A flow chart of the two main experiments conducted in
this study, the AC protein comparison experiment and
the AC proteome evaluation experiment is given in
Figure 1.
The AC protein comparison experiment
In the AC protein comparison experiment the protein
contents of AC fluid from 14 patients (patients 1-14)
were semi-quantitatively compared using a label-free
proteomics approach to determine the protein homoge-
neity across the different patients. The peptides from
each of the 14 patients were analyzed on an ion-trap
mass spectrometer, and the protein extracted ion chro-
matographic (XIC) intensity values, extracted from the
Spectrum Mill searched data, were compared between
the different patients using PCA. In total, 139 proteins
were identified from the 14 different patients. When all
139 proteins were compared using PCA, the two first
principal components (PC) explained 33% of the total
variation in the dataset (Figure 2). As low scoring pro-
teins with few associated spectra can lead to more inac-
curate semi-quantitative measurements, we also
compared the 50 proteins with highest protein scores.
For this dataset, the two first PCs explained 48% of the
total variation in the dataset (Figure 3). This was a lar-
ger degree of explained variation than the model based
on all 139 proteins. A comparison based on the 50 high-
est scoring proteins gave a clearer separation in absolute
distance from the origin for samples from patients 3
(old hematoma), 4 (previous operation) and 12 (slight
observed hemolysis), as well as possibly patient 9, than
for the other patients. To check whether or not this
separation was due to a single or a few proteins, we per-
formed a sub-sampling scheme. Selecting 50 of the 139
proteins at random for 1000 iterations and evaluating
absolute distance in standard deviations from the origin
showed that patients 3, 4 and 12, the samples presumed
to be different, are consistently further away from the
sample mean than the rest of the patients (Table 2),
while this was not the case for patient 9. Disregarding
patients 3, 4 and 12, the dataset of individual patient’s
AC fluid samples presents little systematic variation. We
Figure 1 Flow charts of the experimental procedure for the
arachnoid cyst protein comparison experiment and for the
arachnoid cyst proteome evaluation experiment.
Figure 2 Arachnoid cyst protein comparison experiment (all
proteins). Principal component analysis (PCA) of individual AC fluid
LC-MS/MS results, normalized to sample sum. The figure is based on
evaluation of all 139 proteins. Axis labels are weights of axes and
the amount of total variance explained by the PC. The percentage
of variance explained by the first two PCs was 33%. Observe that
patients 3 and 4, as well as patient 12 were apart from the other
patients.
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did not find that a few specific proteins create the
separation of patients 3, 4 and 12 from the others.
There was no apparent sub-grouping or trends in the
data. The lack of systematic trends is an indication of
homogenous sample material, thus suggesting that AC
is a homogenous condition as evaluated by proteomics.
The AC proteome evaluation experiment
In the AC proteome evaluation experiment, the aim was
to identify the major protein components of AC fluid,
and to qualitatively compare these proteins to the pro-
teins previously identified in CSF and plasma and
thereby learn more about the composition and origin of
AC fluid. Based on the results in the AC protein com-
parison experiment, AC fluid from patients with identi-
fied blood protein haemoglobin in the cyst fluid was
excluded from this analysis (patients 7, 12, 13 and 14).
In this experiment, 10 μg AC fluid from the remaining
11 patients was pooled, digested, fractionated using SCX
chromatography, purified and analyzed on a Q-ToF
mass spectrometer. From these analyses, 199 proteins
were identified in the AC fluid (Additional File 1: List of
199 proteins detected in a pool of AC fluid from 11
patients, with number of peptides and sequence
coverage). The identified proteins spanned a large range
of MWs, with apolipoprotein C-I being the smallest
with a MW of 9.3 kDa, and protocadherin fat 2 being
the largest with a molecular weight of 479.3 kDa. The
isoelectric point of the proteins ranged from 4.35 to
9.96, represented by cell growth regulator with EF hand
domain protein 1 and NANUC-1 heavy chain protein,
respectively. The MW and pI calculations were per-
formed using the Compute pI/Mw tool [24]. The 199
identified proteins were compared based on IPI acces-
sion numbers to published libraries of CSF [18] and
plasma [19] (Figure 4). The database comparison identi-
fied 15 proteins that were not reported in CSF or
plasma and we identified 11 of these by targeted protein
identification in lumbar CSF samples using the MIDAS
workflow on a Q-TRAP 5500 mass spectrometer (Table
3). Hence, most proteins identified in AC fluid (195 out
of 199) were proven to also be present in CSF or
plasma. The four proteins that were not found in the
databases were; Isoform 3 of seizure 6-like protein 2,
full-length cDNA clone CS0DD006YL02 of neuroblas-
toma of Homo sapiens, isoform 2 of neuroendocrine
protein 7B2, and cell adhesion molecule 1 (Table 3).
The overlap between AC fluid and plasma only con-
tained 3 supplementary proteins not identified in CSF,
whereas CSF and AC fluid had 89 proteins in common
but not found in plasma (Figure 4). The 199 identified
Figure 3 Arachnoid cyst protein comparison experiment (top
50 proteins). Principal component analysis (PCA) of individual AC
fluid LC-MS/MS results, normalized to sample sum. The figure is
based on evaluation of top 50 proteins on protein score. Axis labels
are weights of axes, the amount of total variance explained by the
PC. The percentage of variance explained by the first two PCs is
48%. Observe that patients 3 and 4, as well as 12 and possibly 9
were apart from the other patients.
Table 2 Arachnoid cyst fluid protein comparison
experiment: distance in dataset standard deviation from
the origin for each patient
Patient All protein
scores -
figure 2
50 highest
protein scores -
figure 3
1000 iterations of 50
randomly-selected
protein scores
1 0.3 0.3 0.5
2 0.7 0.6 0.7
3 2.3 2.2 2.1
4 1.9 1.9 1.8
5 1.6 1.4 1.7
6 0.9 0.7 1.0
7 1.8 0.4 1.3
8 0.2 0.1 0.8
9 0.0 1.7 0.7
10 1.3 1.0 1.2
11 1.8 1.2 1.5
12 2.3 3.0 1.8
13 0.3 0.3 0.5
14 0.3 0.2 0.4
Evaluation of all 139 proteins (Column 2), the top 50 proteins on protein score
(Column 3) and an average over 1000 reiterations of PCA performed on
pulling 50 of the 139 proteins in a random sub-sampling scheme (Column 4).
The table show that the standard deviations of patient 3, 4 and 12 were
higher than for the others. This was not the case for patient 9. The values
represent the distance from each individual patient to the mean of all
patients, using the first two principal components from the PCA. The results
were normalized with respect to sample standard deviations.
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proteins identified in AC fluid were annotated to a
diverse range of biological processes, molecular func-
tions, and sub cellular compartments using the Protein-
Center, v3.2.0.9 software (Proxeon, Odense, Denmark)
(Figures 5 and 6 and 7). Of the 199 proteins we identi-
fied, 39.6% are involved in transport as a cellular activity
(Figure 5), 20.6% are involved in transport activity on
molecular function (Figure 6), 81.9% are annotated as
extracellular proteins, while 66.8% are membranous pro-
teins (Figure 7). A comparison of molecular functions of
the proteins identified in AC and CSF demonstrated a
similar distribution (Figure 8). Ten genes have pre-
viously been found to be differentially expressed in AC
membranes compared to normal arachnoid; NKCC1 [7]
and ASGR1, DPEP2, SOX9, SHROOM3, A2BP1,
ATP10D, TRIML1, BEND5 and NMU [10]. We did not
find the corresponding protein products among the 199
identified proteins in our study.
Discussion
As far as we know, this is the first study of proteomic
evaluation of AC fluid. In the AC protein comparison
experiment we looked for systematic differences or dis-
tributions between AC from different patients. The
hypothesis underlying this experiment was that the pro-
tein profile in AC fluid would be similar between the
examined patients, and this was supported by our data.
This indicates a common filling mechanism and source
for AC fluid in these patients. Previous observations of
left side domination in males as well as a predilection
for the middle cranial fossa do imply a common origin
of AC fluid between patients. One possible method of
formation is a defect during the embryological develop-
ment of the Sylvian fissure [25]. AC could potentially be
two or more conditions or subgroups with different fill-
ing mechanisms but our proteomics data from the dif-
ferent samples of AC fluid did not support this
hypothesis, as no systematic variation in PCA-plots was
Figure 4 Venn-diagram showing the protein IPI-identity
overlaps between arachnoid cyst fluid, previously recorded
CSF [18] and plasma [19]. Each large circle defines the content of
the three individual dataset. The numbers indicate proteins in each
group, the overlap between larger circles indicate the number of
protein identities in common.
Table 3 Proteins in arachnoid cyst fluid not identified in published libraries of CSF [18] or plasma [19], and peptides
identified from targeted identification in samples of normal CSF
IPI
number
Protein name Molecular weight
(KDa)
# peptides identified
in CSF
IPI00178854 Contactin-4 113.454 1
IPI00332887 cDNA, FLJ92887, Homo sapiens protein tyrosine phosphatase, non-receptor
typesubstrate 1 (PTPNS1), mRNA
54.967 4
IPI00218803 Isoform B of Fibulin-1 77.214 7
IPI00855821 NRXN1-alpha 169.913 4
IPI00018276 Isoform 3 of Seizure 6-like protein 2 97.501 ND
IPI00216250 Cell recognition protein CASPR4 145.660 1
IPI00479708 Full-length cDNA clone CS0DD006YL02 of Neuroblastoma of Homo sapiens (human) 41.273 ND
IPI00022418 Fibronectin 262.625 12
IPI00645363 Putative uncharacterized protein DKFZp686P15220 51.725 7
IPI00470716 Isoform 2 of Neuroendocrine protein 7B2 23.730 ND
IPI00003813 Cell adhesion molecule 1 48.509 ND
IPI00435020 Isoform 2 of Neural cell adhesion molecule 1 94.574 6
IPI00384998 Isoform 7 of Neurofascin 150.027 4
IPI00451624 Cartilage acidic protein 1 71.421 3
IPI00219664 Isoform 2 of Myelin-oligodendrocyte glycoprotein 28.179 1
Proteins that were not found in any of the databases or in the targeted identification experiment is indicated by not detected (ND).
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observed (Figures 2, 3). This finding supports previous
experiments performed by clinical chemistry [9] and
mRNA [10]. We observed some variation for patients 3,
4 and 12, which can be explained by patient 3 having an
old hematoma in close proximity and patient 4 pre-
viously operated for the same condition. Patient 12 had
a slight observed haemolysis of the AC fluid. We had
anticipated a change in the proteome as a consequence
of a local trauma and consecutive repair mechanisms.
There was an increase in the percentage variation
explained by the first two PCA components when look-
ing at only the 50 highest scoring proteins compared to
all 139 proteins. This can be explained by the fact that
low scoring proteins often are represented by few
Figure 5 Biological process involvement of the 199 arachnoid cyst fluid proteins identified, denoted in percentage of proteins. Note
that any one protein may be involved in several processes. Observe that 39.6% of the proteins are involved in transport processes. The figure
was made using ProteinCenter, v3.2.0.9.
Figure 6 Molecular functions of 199 arachnoid cyst fluid proteins identified expressed as percentage of proteins. Note that any one
protein may have several functions. Observe that 20.6% of the proteins are involved in transporter activity. The figure was made using
ProteinCenter, v3.2.0.9.
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peptide observations, which will lead to few values for
semi-quantitative measurements, and the uncertainty in
the measurements is increased. Hence, focusing only on
the proteins with the highest protein scores will give a
more accurate picture of the comparison. The method
of sub-sampling was useful for evaluation of the stability
of a result, such as for the evaluation on whether patient
9 was an actual outlier relative to the remaining patient
samples.
The AC proteome evaluation experiment resulted in
the identification of 199 proteins from pooled AC fluid
from 11 patients. In order to identify more AC proteins
than the 199 we found in our study, more extensive
fractionation of the sample material could have been
done, although this is limited by amount of sample
material, as well as use of mass spectrometers with
higher sequencing capacity and sensitivity. Using lumbar
CSF as the basis for comparison with AC fluid is possi-
ble when doing a qualitative protein comparison, as pro-
teins are not expected to disappear during migration
towards the lumbar area. In a quantitative study
between AC fluid and CSF on the other hand, it would
be important to use CSF collected in the temporal fossa
to avoid effects of the rostro-caudal protein gradients.
Of the 199 proteins we identified 15 were not found
among the reported 2627 proteins in the CSF database
[18] or the 3017 in the plasma database [19]. This does,
however, not imply that these proteins are not present
in CSF or plasma, as they may not have been previously
identified and therefore not added to the database or
they could be in the database but under a different
accession number, leading to a mismatching. This may
explain why we identified 11 of the 15 AC fluid proteins
not found in the CSF or plasma databases, in the col-
lected CSF samples, using targeted identification with
the MIDAS workflow. Hence the number of proteins
that potentially are unique to AC fluid was further
decreased to four proteins after this experiment.
The large overlap between AC fluid proteins and CSF
(192 of 199 proteins in common) indicates that CSF is
important in the filling of the AC. There was much less
overlap between identified plasma proteins and AC fluid
proteins, with 104 proteins only identified in AC fluid.
As the identified protein content of AC almost comple-
tely overlapped with the proteins previously identified in
CSF, it was not surprising that the biological function
annotation of the identified AC fluid also corresponded
well with the annotations of the CSF proteins (Figure 8).
We did not observe that any particular protein group
was not present in AC fluid compared to CSF. In addi-
tion small (9.3 kDa), large (479.3 kDa), basic (pI 9.96),
and acidic (pI 4.35) proteins were observed in AC fluid,
indicating that there were no absolute exclusion of pro-
teins with these different characteristics even though the
most extreme basic and acidic proteins were not
observed. Certain protein groups could be expected to
not be present in AC if there was a selective transport
mechanism of fluid across the AC membrane. There
could, however still be quantitative differences between
certain protein groups in CSF and AC fluid, which
would then point towards properties in the filling
mechanism. Given the high qualitative similarity we
found between AC fluid proteins and CSF proteins, a
relevant future study would be to do a quantitative pro-
tein comparison of the temporal fossa CSF and AC fluid
from the same patient collected at the same time. This
Figure 7 Cellular component localization of 199 arachnoid cyst fluid proteins identified, expressed as percentage of proteins. Note
that each protein may be identified in several localizations. 81.9% of the proteins are annotated as extracellular proteins, while 66.8% are
annotated as membranous proteins. The figure was made using ProteinCenter, v3.2.0.9.
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Figure 8 Comparison of proteins in arachnoid cyst fluid and CSF [18]based on molecular function, expressed as percentage of
proteins. Note a large difference in number of proteins detected and used as a basis for creating the figure: 199 proteins in AC and 2627 in
the CSF database. The figure was made using ProteinCenter, v3.2.0.9.
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would give information about which proteins or protein
classes that are differentially expressed between AC fluid
and CSF in proximity to the AC, possibly giving further
indications of the filling mechanism of AC fluid and the
origin of the AC fluid.
Conclusions
The results of this study indicate that AC fluid is homo-
genous between patients when evaluated by protein con-
tent using a label-free semi-quantitative proteomics
approach, a finding supporting results from previous
experiments regarding clinical chemistry and mRNA.
This points towards a similar filling mechanism of the
AC for the examined patients. We found that most pro-
teins identified in AC fluid also could be identified in
CSF, while plasma had fewer proteins in common with
AC fluid. This indicates that CSF has similar properties
to AC fluid. We did not find specific groups of proteins
with given properties absent from AC fluid, but there
could still be different quantitative trends between CSF
and AC fluid. A future quantitative proteomics compari-
son between CSF and AC collected from the same
patients at the same time would reveal this information.
Additional material
Additional file 1: List of 199 proteins detected in a pool of AC fluid
from 11 patients, with number of peptides and sequence coverage.
Proteins are denoted by lead protein IPI accession number.
Abbreviations
AC: arachnoid cyst; ACN: acetonitrile; AM: arachnoid mater; CSF:
cerebrospinal fluid; DTT: dithiothreitol; FA: formic acid; HPLC: high pressure
liquid chromatography; IAA: iodoacetamide; IDA: information dependent
acquisition; LC: liquid chromatography; MIDAS: multiple reaction monitoring
initiated detection and sequence analysis; MRM: multiple reaction
monitoring; MS: mass spectrometer; ND: not detected; PC: principal
component; PCA: principal component analysis; PPM: parts per million; SCX:
strong cation exchange; TFA: trichloro formic acid; qTOF: quadropole time-
of-flight; XIC: extracted ion chromatographic intensity value.
Acknowledgements
The study was funded by the Western Norway Regional Health Authority
(Helse Vest RHF) and by research allocations from The Meltzer foundation.
The study was also supported in part by the National Program for Research
in Functional Genomics (FUGE) funded by the Norwegian Research Council.
MB thanks the operation theatre staff (SOP) at Haukeland University Hospital
for a positive and helpful attitude towards the project.
Author details
1Institute of Medicine, University of Bergen, 5021 Bergen, Norway.
2Proteomics Unit at University of Bergen (PROBE), Department of
Biomedicine, University of Bergen, 5021 Bergen, Norway. 3Department of
Mathematics, University of Bergen, 5008 Bergen, Norway. 4Department of
Biomedicine, University of Bergen, 5021 Bergen, Norway. 5Department of
Surgical Sciences, University of Bergen, 5021 Bergen, Norway. 6Department
of Neurosurgery, Haukeland University Hospital, 5021 Bergen, Norway.
7Laboratory of Clinical Biochemistry, Haukeland University Hospital, 5021
Bergen, Norway. 8The Norwegian Multiple Sclerosis Competence Centre,
Haukeland University Hospital, Bergen, Norway.
Authors’ contributions
MB, ACK, KW, RJU, CAH, FSB conceived and designed the experiments. ACK,
TTA, JAO, EO performed the experiments. MB, ACK, ØAH, TTA analyzed the
data. KW, CAH operated on the patients. MB performed sample collection
and handling. MB, ACK, ØAH, TTA, JAO, EO, KW, RJU, CAH, FSB wrote the
paper. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 February 2011 Accepted: 20 May 2011
Published: 20 May 2011
References
1. Morris Z, Whiteley WN, Longstreth WT Jr, Weber F, Lee YC, Tsushima Y,
Alphs H, Ladd SC, Warlow C, Wardlaw JM, Al-Shahi Salman R: Incidental
findings on brain magnetic resonance imaging: systematic review and
meta-analysis. BMJ 2009, 339:b3016.
2. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP,
Niessen WJ, Breteler MM, van der Lugt A: Incidental findings on brain MRI
in the general population. N Engl J Med 2007, 357:1821-1828.
3. Helland CA, Lund-Johansen M, Wester K: Location, sidedness, and sex
distribution of intracranial arachnoid cysts in a population-based
sample. J Neurosurg 2010, 113:934-939.
4. Rengachary SS, Watanabe I: Ultrastructure and pathogenesis of
intracranial arachnoid cysts. J Neuropathol Exp Neurol 1981, 40:61-83.
5. Rengachary SS, Watanabe I, Brackett CE: Pathogenesis of intracranial
arachnoid cysts. Surg Neurol 1978, 9:139-144.
6. Galassi E, Tognetti F, Gaist G, Fagioli L, Frank F, Frank G: CT scan and
metrizamide CT cisternography in arachnoid cysts of the middle cranial
fossa: classification and pathophysiological aspects. Surg Neurol 1982,
17:363-369.
7. Helland CA, Aarhus M, Knappskog P, Olsson LK, Lund-Johansen M, Amiry-
Moghaddam M, Wester K: Increased NKCC1 expression in arachnoid cysts
supports secretory basis for cyst formation. Exp Neurol 2010, 224(2):424-.
8. Go KG, Houthoff HJ, Blaauw EH, Havinga P, Hartsuiker J: Arachnoid cysts of
the sylvian fissure. Evidence of fluid secretion. J Neurosurg 1984,
60:803-813.
9. Berle M, Wester KG, Ulvik RJ, Kroksveen AC, Haaland OA, Amiry-
Moghaddam M, Berven FS, Helland CA: Arachnoid cysts do not contain
cerebrospinal fluid: A comparative chemical analysis of arachnoid cyst
fluid and cerebrospinal fluid in adults. Cerebrospinal Fluid Res 2010, 7:8.
10. Aarhus M, Helland CA, Lund-Johansen M, Wester K, Knappskog PM:
Microarray-based gene expression profiling and DNA copy number
variation analysis of temporal fossa arachnoid cysts. Cerebrospinal Fluid
Res 2010, 7:6.
11. Zhu W, Smith JW, Huang CM: Mass spectrometry-based label-free
quantitative proteomics. J Biomed Biotechnol 2010, 2010:840518.
12. Sandberg DI, McComb JG, Krieger MD: Chemical analysis of fluid obtained
from intracranial arachnoid cysts in pediatric patients. J Neurosurg 2005,
103:427-432.
13. Wester K, Helland CA: How often do chronic extra-cerebral haematomas
occur in patients with intracranial arachnoid cysts? J Neurol Neurosurg
Psychiatry 2008, 79:72-75.
14. Berven FS, Kroksveen AC, Berle M, Rajalahti T, Flikka K, Arneberg R,
Myhr KM, Vedeler CA, Kvalheim OM, Ulvik RJ: Pre-analytical influence on
the low molecular weight cerebrospinal fluid proteome. Proteomics Clin
Appl 2007, 1:699-711.
15. Unwin RD, Griffiths JR, Whetton AD: A sensitive mass spectrometric
method for hypothesis-driven detection of peptide post-translational
modifications: multiple reaction monitoring-initiated detection and
sequencing (MIDAS). Nat Protoc 2009, 4:870-877.
16. [http://www.uib.no/rg/probe/publications/software/pklfilemerger].
17. [http://www.proteomesoftware.com].
18. Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, Purvine SO,
Hixson KK, Lipton MS, Camp DG, Coyle PK, Smith RD, Bergquist J:
Establishing the proteome of normal human cerebrospinal fluid. PLoS
One 2010, 5:e10980.
19. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H,
Apweiler R, Haab BB, Simpson RJ, Eddes JS, Kapp EA, Moritz RL, Chan DW,
Rai AJ, Admon A, Aebersold R, Eng J, Hancock WS, Hefta SA, Meyer H,
Berle et al. Fluids and Barriers of the CNS 2011, 8:19
http://www.fluidsbarrierscns.com/content/8/1/19
Page 11 of 12
Paik YK, Yoo JS, Ping P, Pounds J, Adkins J, Qian X, Wang R, Wasinger V,
Wu CY, Zhao X, et al: Overview of the HUPO Plasma Proteome Project:
results from the pilot phase with 35 collaborating laboratories and
multiple analytical groups, generating a core dataset of 3020 proteins
and a publicly-available database. Proteomics 2005, 5:3226-3245.
20. [http://geneontology.org].
21. Johnson RA, Wichern DW: Applied Multivariate Statistical Analysis. 5 edition.
Upper Saddle River, N.J: Prentice Hall; 2001.
22. Meinshausen N, Bühlmann P: Stability Selection. J R Statist Soc B (2010)
2010, 72:417-473.
23. Bühlmann P, Yu B: Analyzing Bagging. The Annals of Statistics 2002,
30:927-961.
24. [http://au.expasy.org/tools/pi_tool.html].
25. Wester K: Peculiarities of intracranial arachnoid cysts: location, sidedness,
and sex distribution in 126 consecutive patients. Neurosurgery 1999,
45:775-779.
doi:10.1186/2045-8118-8-19
Cite this article as: Berle et al.: Protein profiling reveals inter-individual
protein homogeneity of arachnoid cyst fluid and high qualitative
similarity to cerebrospinal fluid. Fluids and Barriers of the CNS 2011 8:19.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Berle et al. Fluids and Barriers of the CNS 2011, 8:19
http://www.fluidsbarrierscns.com/content/8/1/19
Page 12 of 12
III

 Quantitative proteomics comparison of arachnoid cyst fluid and 
cerebrospinal fluid collected perioperatively from arachnoid 
cyst patients  
 
Authors and Affiliations 
Magnus Berle 1,2,3§, Ann Cathrine Kroksveen 2,4, Hilde Garberg 2, Mads Aarhus 5,6, Øystein A. 
Haaland 7, Knut Wester 3,8, Rune J. Ulvik 1,9, Christian Helland 3,8, Frode Berven 2,10 
 
1Department of Medicine, University of Bergen, Norway 
2Proteomics Unit (PROBE), Department of Biomedicine, University of Bergen, Norway 
3Department of Surgical Sciences, University of Bergen, Norway 
4The KG Jebsen Centre for MS-research, Department of Clinical Medicine, University of 
Bergen, Norway. 
5Department of Neurosurgery, Oslo University Hospital, Norway 
6Centre for Medical Genetics and Molecular Medicine, Haukeland University Hospital, 
Norway 
7Department of Public Health and Primary Health Care, University of Bergen, Norway 
8Department of Neurosurgery, Haukeland University Hospital, Norway 
9Laboratory of Clinical Biochemistry, Haukeland University Hospital, Norway. 
10The Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, 
Norway. 
 
§Corresponding author 
 
Email addresses 
 MB: magnus.berle@gmail.com 
 ACK: ann.kroksveen@biomed.uib.no 
 HG: hilde.garberg@biomed.uib.no 
 MA: mads.aarhus@me.com 
 OAH: oystein.haaland@isf.uib.no 
 KW: kgwe@helse-bergen.no 
 RJU: rune.ulvik@med.uib.no 
 CAH: christian.helland@kir.uib.no 
 FSB: frode.berven@biomed.uib.no 
  
Abstract 
Background: There is little knowledge concerning the content and the mechanisms of filling 
of arachnoid cysts. The aim of this study was to compare the protein content of arachnoid 
cysts and cerebrospinal fluid by quantitative proteomics to increase the understanding of 
arachnoid cysts. 
 
Methods: Arachnoid cyst fluid and cerebrospinal fluid from five patients were analyzed by 
quantitative proteomics in two separate experiments. 
In a label-free experiment arachnoid cyst fluid and cerebrospinal fluid samples from 
individual patients were trypsin digested and analyzed by Orbitrap mass spectrometry in a 
label-free manner followed by data analysis using the Progenesis software. 
In the second proteomics experiment, a patient sample pooling strategy was followed by 
MARS-14 immunodepletion of high abundant proteins, trypsin digestion, iTRAQ labelling, 
and peptide separation by mix-phase chromatography followed by Orbitrap mass 
spectrometry analysis. The results from these analyzes were compared to previously 
published mRNA microarray data obtained from arachnoidal membranes. 
 
Results: We quantified 348 proteins by the label-free individual patient approach and 1425 
proteins in the iTRAQ experiment using a pool from five patients of arachnoid cyst fluid and 
cerebrospinal fluid. This is by far the largest number of arachnoid cyst fluid proteins ever 
identified, and the first large-scale quantitative comparison between the protein content of 
arachnoid cyst fluid and cerebrospinal fluid for the same patients at the same time. 
Consistently in both experiment, we found 22 proteins with significantly increased abundance 
in arachnoid cysts compared to cerebrospinal fluid and 24 proteins with significantly 
decreased abundance. We did not observe any molecular weight gradient over the arachnoid 
cyst membrane. Of the 46 proteins we identified as differentially abundant in our study, 45 
were also detected from the mRNA expression level study. None of them were previously 
reported as differentially expressed. We did not quantify any of the proteins corresponding to 
gene products from the ten genes previously reported as differentially abundant between 
arachnoid cysts and control arachnoid membranes.  
 Conclusions: From our experiments, the protein content of arachnoid cyst fluid and 
cerebrospinal fluid appears to be similar. There was however proteins significantly 
differentially abundant between arachnoid cyst fluid and cerebrospinal fluid. This could 
reflect that these proteins are affected by the filling mechanism of arachnoid cysts or are shed 
from the membranes into arachnoid cyst fluid. Our results do not support the proposed filling 
mechanisms of oncotic pressure or valves. 
 
Introduction 
Arachnoid cysts (AC) are congenital malformations of the arachnoid; a benign malformation 
with reported prevalence of up to 1.1 % [1, 2]. The mechanism of formation of such cysts is 
not known, although several studies have tried to investigate and understand the biological 
basis of AC [3-11]. Anatomically, AC originate from splitting of the arachnoid mater (AM), 
thus AC are truly intra-arachnoid in nature [9, 10]. True AC are considered to be 
developmental or congenital mistakes of the arachnoid architecture [12]. By electron 
microscopy, Rengachary et al [10] observed that the inner membrane of AC is covered by 
hyperplastic arachnoid cells, as well as cells in the cyst membrane – resembling foetal human 
arachnoid cells.  
 
Using chemical analyses on AC fluid, Sandberg et al [7] observed composition comparable 
with cerebrospinal fluid (CSF). In addition, they found that some cysts had elevated protein 
levels in their fluid, relative to reference values. In a previous study on AC fluid and CSF 
from the same patient population as the current study, Berle et al [4] found AC fluid and CSF 
to be similar in electrolyte content, except for an increased phosphate content in cyst fluid. 
The following components were reduced in AC fluid compared with CSF: 1) the total protein 
amount 2) lactate dehydrogenase and ferritin. Based on the decrease in protein concentration, 
we would suspect a molecule weight gradient, although the number of measured proteins was 
low.  
Helland et al [5] and Aarhus et al [6] found differentially expressed mRNA and DNA copy 
number in AC membrane relative to normal arachnoid membrane for the genes 
[5] 
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The NKCC1 is an active salt pump, that conceptually could contribute to the filling of AC. 
Zeuthen [13] discussed water transport in tissues against osmotic barriers and suggested that 
this transport is energised by ion transport, thus opening for active or selective transport as a 
filling mechanism. For active pumps such as the sodium – potassium – chloride transporter 
NKCC1, the amount of water co-transported is interesting - a single load of 1 Na+, 1 K+, 2 Cl- 
may co-transport as much as 590 H20-molecules. 
 
In the same patient population as the current study, Berle et al [11] performed a qualitative 
proteomics study of AC fluid, where the 199 identified proteins in a pool from 11 individual 
patients did show a similar protein expression as in normal CSF (195/199 proteins), dissimilar 
from that of plasma. A qualitative protein comparison study between 14 patients did indicate 
AC fluid protein profiles to be relatively homogenous between patients.  
 
Label-free quantitative proteomics by measured precursor intensity is a well-established 
method for obtaining relative quantitative measurements of a large number of proteins 
between samples [14]. Quantitative proteomics by Isobaric tag for relative and absolute 
quantification (iTRAQ) [15] allows for extensive fractionation at the peptide level of samples 
pooled after labeling without loosing analytical reproducibility. The possibility for extensive 
fractionation makes it possible to identify and quantify a larger portion of the proteome. This 
provides in part qualitative information of the proteome of AC. The quantitative proteomics 
methods applied here is thoroughly revised elsewhere [16]. 
 
In this study we used proteomics to quantitatively compare the protein content of AC fluid 
and CSF from the same patients, in order to identify possible differences in the proteomes 
between these two fluids. Two different approaches were undertaken; one where samples 
from individual patients were analysed using a label-free approach, and one where individual 
patient samples were pooled, iTRAQ-labelled and extensively fractionated to allow for a 
more in-depth quantitative analysis of the proteomes. The results form the two 
complementary proteomics approaches were expected to give us a better insight in the content 
of AC fluid and potentially the mechanisms of fluid filling. Furthermore, we wanted to use 
the quantitative data to evaluate previously published results on AC, both to test the 
hypothesis of a molecular weight gradient over the AC membrane, and the comparison to 
previous published DNA and mRNA-results.  
Materials and Methods 
Participants  
Five participants, two males, three females, age 26-60 years, with unilateral temporal AC 
were included in this study (Table 1). AC fluid was collected during decompressive cyst 
surgery at Haukeland University Hospital (Bergen, Norway). The samples were selected from 
our biobank, that contains samples of AC fluid and CSF from the same patients. All the 
patients fulfilled the following criteria: no previous intracraial surgery, no intracranial 
bleeding or trauma, and relatively low intraoperative blood contamination in both AC fluid 
and CSF as estimated from visual inspection and measured by mass spectrometry.  
 
The methods for sample collection and handling protocol as well as the laboratory work-up 
used in this study have previously been described in detail [4, 17]. Briefly, AC fluid was 
collected during elective surgery for AC (craniotomy with fenestration and extirpation of the 
cyst) by puncturing the dura with a 23G, 25mm long syringe needle using an Optidynamic® 
spinal fluid manometer (Mediplast AB, Malmo, Sweden) as siphon through a burr hole before 
the craniotomy and opening of the dura. The fluid was centrifuged at 450 x g for 5 minutes to 
remove cells and cell debris, and the supernatant was aliquoted and frozen at -80 °C. 
Deviations and observations on individual sample material were noted on sampling.  
 
After opening the medial cyst membrane that covered the basal structures (the tentorial slit, 
the oculomotor nerve, the carotid artery, and the optic nerve), thus creating communication to 
the basal cisterns and the posterior fossa, a CSF-sample was collected with a pre- cut baby-
feeding catheter #6, connected to a 10 ml syringe. The catheter was placed below the 
tentorium via the tentorial slit and fluid was aspirated gently from the posterior fossa. The 
collected CSF was processed in the same manner as the cyst fluid. 
 
An overview of the procedures is given in Figure 1.   
  
Chemicals 
Trypsin was purchased from Promega (Fitchburg WI, USA). N-octyl-β-D-glycopyranoside 
(NOG) was purchased from Anatrace (Maumee, OH, USA). Urea, acetonitrile (ACN), formic 
acid (FA), calcium chloride (CaCl2), iodoacetamide (IAA) and dithiothreitol (DTT), 
potassium phosphate monobasic (KH2PO4), potassium chloride (KCl), water and 
trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (St. Louis MO, USA). Water 
and ACN were of HPLC quality.  
Lable free sample preparation 
The protein concentration in AC fluid was measured using a Qubitfluorometer (Life 
Technologies, Carlsbad CA, USA). The individual AC fluid and CSF samples were 
concentrated and desalted using Amicon 3 kDa molecular weight cut-off filters (Millipore, 
Billerica, MA, USA) and dried in a vacuum concentrator (Eppendorf, Hamburg, Germany). 
The proteins were digested into peptides by trypsin as described [18], a brief summary 
follows: the dried protein pellet was dissolved in 6M Urea and 100mM DTT and incubated 
for 1h at room temperature (RT). Cysteins were alkylated using 200 mM iodoacetamide 
during one hour incubation at RT. Chymotrypsin activity was inhibited by adding 2 mM 
CaCl2 and
 
the proteins were digested to peptides over night at 37°C using trypsin 
(Sequencing Grade Modified Trypsin, Promega) at a protein:trypsin ratio of 1:50. Each 
sample was acidified using 10 % FA to quench the digestion activity, desalted and 
concentrated on an Oasis HLB Elution Plate (Waters) as previously described [14] followed 
by drying the sample completely in a vacuum concentrator.  
 
Sample preparation prior to iTRAQ-labelling 
150 l AC fluid from each of the five patients was used to generate a pool of 750 l, and a 
pool of CSF was made in the same way for the same patients. 250 l of each of these two 
pools were combined into a mix-pool. 500 l from each of the AC fluid pool, CSF pool and 
mix-pool was concentrated using 3 kDa ultracentrifugation filters (Amicon Ultra-4, Millipore, 
Bedford, MA), which were pre-rinsed with 0.1 % NOG. The samples were then depleted from 
high abundant proteins using a human Multiple Affinity Removal System (MARS Hu-14) 4.6 
mm × 50 mm LC column (Agilent Technologies) according to the protocol provided by the 
supplier, using a Dionex 3000-series LC system. This column depletes albumin, IgG, 
antitrypsin, IgA, transferrin, haptoglobin, fibrinogen, alpha-2-macroglobulin, alpha-1-acid 
glycoprotein, IgM, apolipoprotein AI, apolipoprotein AII, complement C3, and transthyretin. 
The high abundant protein depleted samples were concentrated using 3 kDa 
ultracentrifugation filters which were pre-rinsed with 0.1 % NOG. Each sample was freeze-
dried prior to protein digestion and iTRAQ labelling.   
Protein digestion and iTRAQ-labelling 
For the pooled patient samples, the entire amount of protein in each depleted sample was 
reduced, alkylated, digested with trypsin, and iTRAQ-labeled according to the manufacturer's 
protocol using the reagents provided (Applied Biosystems, Foster City, CA). The reduced and 
S-methylmethanethiosulfonate (MMTS) treated proteins were digested to peptides over night 
at 37 °C using 2.5 g trypsin as protease. The peptides were iTRAQ-labeled (4plex) where 
the mix-pool 50:50 AC fluid and CSF with the 114 label, the AC fluid with 115, and CSF 
with 116. All samples were combined after the labeling was conduced. 
Mix-phase chromatograpy  
iTRAQ labelled peptides were fractionated in 28 fractions using mix-phase chromatography 
utilizing a Sielc Promix column (MP-10.250.0530, 1.0 x 250 mm, 5 μm, 300Å, Sielc 
Technologies, Prospect Heights, Illinois), using an Agilent 1260 series LC system (Agilent 
Technologies, Palo Alto, CA).  The peptides were reconstituted in buffer A (20 mM 
ammuniumformate, 3 % ACN) and loaded on the Mix phase column using 85 % A for 10 
minutes at a flowrate of 50 μl/min. The peptides were eluted using a gradient of 15 % - 60 % 
buffer B (2mM ammonium formate, 80 % ACN, pH 3.0) over 35 minutes, 60 %-100 % B 
over 10 minutes and hold constant for 5 minutes. The fractions were collected every 2 
minutes until 60 minutes, the last 10 minutes of the LC run was collected in 2 fractions of 5 
minutes. The fractions from the 8 first minutes of the gradient were discarded. 
 
Orbitrap mass spectrometry 
 
Injection and LC 
About 0.5μg of each peptide sample, dissolved in 1 % aqueous formic acid, were injected into 
an Ultimate 3000 RSLC system (Thermo Scientific, Sunnyvale, California, USA) connected 
online to a linear quadrupole ion trap-Orbitrap (LTQ-Orbitrap Velos Pro) mass spectrometer 
(Thermo Scientific, Bremen, Germany) equipped with a nanospray Flex ion source (Thermo 
Scientific). 
The sample was loaded and desalted on a pre-column (Acclaim PepMap 100, 2cm x 75µm 
i.d. nanoViper column, packed with 3µm C18 beads) at a flow rate of 5µl/min for 6 min using 
an isocratic flow of 0.1 % FA (vol/vol) with 2 % ACN (vol/vol). 
Peptides were separated during a biphasic ACN gradient from two nanoflow UPLC pumps 
with flow rate of 280 nl /min on the analytical column (Acclaim PepMap 100, 15 cm x 75µm 
i.d. nanoViper column, packed with 2µm C18 beads). Solvent A was 0.1 % FA (vol/vol) with 
2 % ACN (vol/vol). Solvent B was 0.1 % FA (vol/vol) with 90 % ACN (vol/vol). The 
gradient composition was 5-38 % B from LC starts to 67 minutes, then 38-90 % B from 67-70 
minutes. 90 % B was held constant for 5 minutes, followed by column conditioning for 12 
minutes with 5 % B. 
 
Individual patient samples 
The eluting peptides were ionised in the electrospray and analyzed by the LTQ-Orbitrap 
Velos Pro. The mass spectrometer was operated in the DDA-mode (data-dependent-
acquisition) to automatically switch between full scan MS and MS/MS acquisition.  
Survey full scan MS spectra (from m/z 300 to 2000) were acquired in the Orbitrap with 
resolution R = 60000 at m/z 400 (after accumulation to a target value of 1e6 in the linear ion 
trap with maximum allowed ion accumulation time of 500ms). The seven most intense eluting 
peptides above an ion threshold value of 1000 counts, and charge states 2 or higher, were 
sequentially isolated to a target value of 1e4 and fragmented in the high-pressure linear ion 
trap by low-energy CID (collision-induced-dissociation) with normalised collision energy of 
40 % and wideband-activation enabled. The maximum allowed accumulation time for CID 
was 200ms, the isolation width maintained at 2Da, activation q = 0.25, and activation time of 
10ms. The resulting fragment ions were scanned out in the low-pressure ion trap at normal 
scan rate, and recorded with the secondary electron multipliers.  One MS/MS spectrum of a 
precursor mass was allowed before dynamic exclusion for 30s. Lock-mass internal calibration 
was not enabled. 
 
Pooled patient samples 
The settings were identical to those mentioned above for CID fragmentation, with the exception 
that the seven most intense eluting peptides were sequentially isolated in the high-pressure 
linear ion trap by low-energy CID and in the octopole HCD collision cell by HCD (Higher 
Energy Collision Dissociation) fragmentation. Both fragmentation forms used normalised 
collision energy of 40 %. For HCD fragmentation the isolation with was 3Da and the 
activation time 0.10ms. After fragmentation in the HCD cell the fragments are transferred via 
the C-trap to the Orbitrap and scanned out with resolution R = 7500. One MS/MS spectrum of 
a precursor mass was allowed before dynamic exclusion for 20s. 
Ethics 
Patients were recruited by the responsible surgeon and had signed a written informed consent. 
This project was approved by the Regional Committee for Medical and Health Research 
Ethics (REK) of Western Norway (approvals REK 70.03, NSD 9634 and REK 2009/1885). 
 
Data analysis 
The handling of multiple testing and validation of peptide and protein hits were assessed by 
false discovery rate (FDR) [19]. The data from the individual patients label-free experiment 
were compared by paired 2-sided t-test with p < 0.05.  
 
The individual patient data obtained from the label-free quantitative analysis was compared 
using Progenesis LC-MS (Nonlinear Dynamics Ltd. Newcastle upon Tyne, UK) 
(v4.0.4573.30654). The data was searched against the SwissProtKB database (release 
2011_10) using SearchGUI (1.8.3) with OMSSA and XTandem as search engines and 
PeptideShaker (0.16.2) (http://code.google.com/p/peptide-shaker/) for combining the results 
[20]. The following search criteria were used: fixed modifications carbamidomethylation, 
oxidated methionin as variable modification, a maximum of two missed cleavages, precursor 
mass tolerance 15 ppm, and product mass tolerance 0.7 Da. The peptides were auto-validated 
with maximum FDR of 1.0 %. The quantitative data obtained from the individual patients in 
the label-free experiment was compared by a paired 2-sided t-test. Proteins with a p-value of 
less than 0.05 combined with an average fold change of more than +/- log2 (0.58)  (Fold 
change >1.5 or <0.67) were considered as differentially abundant between CSF and AC fluid. 
 
The pooled patient iTRAQ-data was searched using the Spectrum Mill software package v4.0 
(Agilent Technologies, Santa Clara, CA) using the same settings as previously described [14]. 
MS/MS data was searched against the SwissProtKB database (release 2011_10) with a 
precursor mass tolerance of 15 ppm, and a product mass tolerance 0.7 Da. The peptides were 
validated by auto-determined score by delta R1-R2 threshold with max FDR of <1.2 %. 
Proteins were validated by minimum protein score of 20. The quantitative data were 
recentered to obtain an average ratio of 1 for each iTRAQ-channel relative to the mix-pool 
reference sample. The reference/CSF value was divided by the reference/AC fluid value for 
every protein to obtain a CSF-to-AC fluid ratio. All proteins with a fold change more than +/- 
log2 (0.58)  (Fold change >1.5 or <0.67) were considered as differentially abundant between 
CSF and AC fluid. 
 Using the bioinformatic software J-Express Pro 2.7 (
	) proteins 
with increased or reduced abundance between CSF and AC fluid in both label-free and 
iTRAQ labelled experiments were compared with the corresponding gene expresson profiles 
of a previously published study [6]. The objective of this examination was to evaluate 
whether AC fluid protein expression could be linked to membrane mRNA expression. The 
proteins were searched in PubMed for official gene symbol, and then searched against the 
microarray data to obtain the corresponding mRNA expression profile. 
 
Gene ontology data for the identified proteins in the iTRAQ experiment were obtained using 
ProteinCenter version 3.9.10025 (Thermo-Fischer scientific, Odense, Denmark). 
Results 
In the quantitative individual label-free comparison, we quantified 348 proteins, of which 150 
were differentially expressed between AC and CSF (p < 0.05 in a paired two-sided t-test, 
minimum 2 peptides, FDR < 1.0 %). In the iTRAQ-labeled quantitative experiment, 1425 
proteins were identified (minimum 2 peptides, FDR <1.2 %). 296 protein groups were 
identified both in the label-free and the iTRAQ-labelled experiment. The list of proteins 
identified from the quantitative iTRAQ-labelled experiment, ranked by fold change AC/CSF 
is presented in Supplementary table 1. Proteins identified in the label-free experiment with 
individual and average fold change, p-value and corresponding iTRAQ fold change value 
(when applicable) are shown in Supplementary table 2. This iTRAQ quantification 
experiment is also the single largest qualitative characterization of AC fluid proteins. The 
1425 proteins quantified in the iTRAQ-experiment were annotated to a multitude of cellular 
localizations, of which the principal classes are presented in Figure 2. A high proportion of 
the proteins were annotated to extracellular or membrane space. Note that one protein may be 
allocated to several localizations and may therefore be counted more than once.  
 
Examining the proteins with significantly differential abundance by t-test between individual 
samples, as well as fold change +/- log2 (0.58)  (Fold change >1.5 or <0.67) in both 
individual label-free samples as well as pooled iTRAQ-labelled samples. We found 22 
proteins with significantly higher abundance in the AC fluid relative to CSF and 24 proteins 
with significantly lower abundance (Table 2). Concerning the proteins with changed 
abundance in AC fluid relative to CSF, we observed no specific pattern in the type of 
proteins. Some, but not all, of the proteins with reduced abundance in AC relative to CSF are 
typical blood proteins. Examples of such proteins were carbonic anhydrase 1, fibrinogen, 
alpha-1-antitrypsin and haemoglobin. Carbonic anhydrase 1 has previously been reported to 
be present in CSF due to contamination of blood introduced during sample collection [21].  
 
Among the proteins being more abundant in AC fluid was ribonuclease T2 (Gene name: 
RNASET2). Defects in RNASET2 are proposed to be the cause of leukoencephalopathy 
cystic without megalencephaly (LCWM), and the brain of such affected indivuduals shows 
anterior temporal lobe subcortical cysts.  
 
We were not able to link the molecular functions of the 46 differentially abundant proteins to 
the cyst fluid biology based on the examined GO functional terms and Uniprot functional 
annotation (data not shown). The cellular location of the differentially abundant proteins 
between AC fluid and CSF were mainly membrane and secreted proteins as seen from the GO 
analysis (data not shown). 
 
In the iTRAQ quantification, we identified 1129 proteins that were not present in the list from 
the label-free experiment. The depletion of the most abundant proteins as well as more 
extensive fractionation caused this increase in the number of proteins quantified. We observed 
that 480 of the proteins quantified in the iTRAQ experiment were outside the selected 
boundaries of significant fold change (+/- log2 (0.58)), but we cannot from this experiment 
conclude if any of these proteins represent a true biological change in abundance without 
additional verification. We observe that these 480 proteins to a lesser degree seem to 
represent membrane or extracellular proteins, relative to the proteins reported as differential 
abundant in both experiments (data not shown). 
 
From the 46 proteins we identified as differentially abundant in our study, 45 were also 
detected from the mRNA expression level study. None of them were reported as differentially 
expressed [6]. We identified no specific patterns of altered abundance between the membrane 
mRNA and the 46 differentially abundant cyst fluid proteins (Supplementary table 3). We did 
not quantify any of the proteins associated with the ten genes previously reported as 
differentially abundant between AC membrane and AM [5, 6] (data not shown). 
 
To test the hypothesis of molecular weight gradients over the AC membrane, we created a 
scatter plot for all the iTRAQ protein ratios sorted based on protein molecular weight. We 
could not see any correlation between increased molecular weight and decreased abundance 
in AC compared to CSF from this plot (results not shown).  
Discussion 
In this study, we identified by far the largest number of AC fluid proteins ever reported, and 
this is also the first large-scale quantitative comparison between the protein content of AC 
fluid CSF collected from the same patients. At present, there are three dominating hypotheses 
on the mechanisms of filling and sustaining of AC: secretion or selective transport, oncotic 
filling, and a slit-valve mechanism. Previous reports of reduced protein content in AC fluid 
relative to CSF [4, 7] do weaken the hypothesis of filling by oncotic pressure.  
 
From our two quantitative proteomics experiments, we identified 46 proteins with altered 
abundance between AC fluid and CSF. Some of the protein groups with lower abundance in 
AC fluid seem to have a high representation of blood proteins. Blood contamination is an 
obvious problem when sampling is not identical between the sample types to be compared, in 
this case AC fluid and CSF. Because we sample AC fluid through a syringe needle after a 
direct puncture of the cyst, the risk for blood contamination is low. CSF is collected in the 
basal cistern after the operation is finished and haemostasis is ensured. This might lead to 
might be a small and variable contamination of blood in the CSF samples. Hence, abundance 
changes in these typical blood proteins are probably not representing AC biology, but are 
rather introduced to CSF during sample collection. Currently, there is no consensus on how to 
handle skewed blood contamination. Most of proteins with reduced abundance in AC relative 
to CSF are however not termed “blood specific” proteins.  
 
A challenge in the evaluation of quantitative difference is the defining criteria on what is 
differentially abundant protein. In our case, we choose to include proteins that were observed 
with fold change above +/- log2 (0.58) in both experiments, as well as a p-value below 0.05 
for the label-free experiment. This result might be somewhat conservative for exploratory 
analyses, hence we also evaluated the abundance changes for the 1129 proteins only 
quantified in the iTRAQ study.  
The 480 proteins from the iTRAQ study with fold change above +/- log2 (0.58) in this 
analysis does however need further verification in different sample sets, by different methods 
or specific validation by for example selective reaction monitoring to increase the certainty of 
these findings. Further verification is also necessary to confirm the differential abundance of 
the 46 proteins found as differentially abundant in both experiments in a larger number of 
patients. Our current results does however support to the previous claim [4] that AC fluid is 
different from CSF. As observed from our Qubit protein measurements, the general trend of 
reduced total protein concentration in AC fluid relative to CSF does not support oncotic 
pressure gradients. Observing differential abundance of proteins between AC fluid and CSF, 
as well as the lack of observed slit valves in general in the literature, do in principle not 
support the theory of valve mechanism but is no definitive evidence. Differential abundance 
of proteins between AC fluid and CSF is supportive of some kind of secretion or selective 
transport, but we are not able to elute which.   
 
Previous reports have identified an up-regulation of mRNA for several ion transporters [5] 
and other genes [6] in AC membrane when compared with normal arachnoidea membrane. In 
our proteomics study, we hypothesised that some of the proteins in the AC membrane 
corresponding to these mRNA transcripts also could be found in the AC fluid, but not to the 
same extend in CSF, and that such proteins possibly could indicate the mechanism of 
transport over the membrane. However, we were not able to draw such lines based on our 
obtained data. Concerning the proteins that make up active pumps, such as NKCC1, they 
would be a part of the AC wall and thus probably not detectable in AC fluid due to the 
hydrophobic nature of such membrane proteins. A lack of confirmation in our data do 
therefore not exclude that such pumps can be found in the AC membrane, in particular since 
hydrophobic membrane proteins might not at all be detectable in the AC fluid due to 
solubility issues.  
 
In a previous study, Berle et al [4] suggested a MW gradient from the reported reduced 
concentration of macromolecules ferritin and lactate dehydrogenase. The extended 
examinations of the data presented in the current work, contradict such a hypothesis of MW 
gradients over the AC membrane.  
Conclusions: 
From our experiments, the protein content of AC fluid and CSF appears to be very similar. 
Some proteins were, however, significantly differentially abundant between AC fluid and 
CSF. This could reflect that these proteins are affected by the filling mechanism of arachnoid 
cysts or are shed from the membranes into arachnoid cyst fluid. Our results do not support the 
mechanisms of oncotic pressure or valves. Based on these results we suggest that AC filling is 
caused by secretion or selective transport across the membrane.  
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Figure Legends 
Figure 1: Overview of procedures undertaken 
 
Figure 2: Genetic Ontology of cellular localization of the 1425 quantified protein groups in 
the iTRAQ-labeled pooled patient samples. Figure made utilizing ProteinCenter version 
3.9.10025. 
 
Tables 
Table 1 - Age, gender and protein concentration in AC fluid and CSF for the included 
patients. 
 
Table 2:  Proteins with different abundance between AC fluid and CSF, determined by 
significant (p < 0.05) differential abundance in individual label-free samples, as well as fold 
change +/- log2 (0.58)  (Fold change >1.5 or <0.67) in both label-free and iTRAQ experiment 
 
Supplementary table 1: Proteins identified in the iTRAQ-labelled experiment, ranked by fold 
change between AC fluid and CSF. 
 
Supplementary table 2: Proteins identified in the label-free experiment with individual and 
average fold change, p-value and corresponding iTRAQ fold change value (when applicable). 
 
Supplementary table 3: Proteins with increased or decreased abundance in AC fluid relative to 
CSF, plotted against corresponding membrane mRNA microarray data in order of 
significance in membrane data.  
  
 
Figure 1 
 
 
 
 
 
Figure 2 
 
 Patient 
number Age Gender 
protein 
content AC 
fluid µg/µl 
protein 
content CSF 
µg/µl 
1 27 f 0,44 0,57 
2 44 m 0,38 0,62 
3 23 f 0,31 0,59 
4 42 f 0,29 0,59 
5 61 m 0,50 0,59 
Average   0,38 0,59 
protein content 
ratio AC fluid / 
CSF  
 
 0,65 
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